UNIVERSITY OF BIRMINGHAM University of Birmingham Research at Birmingham

Risk factors for developing COVID-19

Holt, Hayley; Dietrich, Thomas; Chapple, lain

DOI: 10.1136/thoraxjnl-2021-217487

License: None: All rights reserved

Document Version Peer reviewed version

Citation for published version (Harvard):

Holt, H, Dietrich, T & Chapple, I 2021, 'Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)', *Thorax.* https://doi.org/10.1136/thoraxjnl-2021-217487

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

"This article has been accepted for publication in Thorax, 2021 following peer review, and the Version of Record can be accessed online at Holt H, Talaei M, Greenig M, et alRisk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)Thorax Published Online First: 30 November 2021. doi: 10.1136/thoraxjnl-2021-217487

© Author(s) (or their

employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)

•Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)

Hayley Holt^{1,2,3*} Mohammad Talaei^{1*} Matthew Greenig¹ Dominik Zenner¹ Jane Symons⁴ Clare Relton¹ Katherine S Young^{5,6} Molly R Davies⁵ Katherine N Thompson⁵ Jed Ashman¹ Sultan Saeed Rajpoot¹ Ahmed Ali Kayyale¹ Sarah El Rifai¹ Philippa J. Lloyd¹ David A. Jolliffe^{1,3} Sarah Finer¹ Stamatina Iliodromiti1 Alec Miners⁷ Nicholas S. Hopkinson⁸ Bodrul Alam⁹ Graham Lloyd-Jones¹⁰ Thomas Dietrich¹¹ lain Chapple¹¹ Paul E Pfeffer¹ David McCoy¹ Gwyneth A Davies¹² Ronan A Lyons¹² Christopher J Griffiths^{1,2} Frank Kee¹³ Aziz Sheikh¹⁴

Gerome Breen⁵ Seif O Shaheen^{1*} Adrian R Martineau^{1,2,3*†} ¹Institute of Population Health Sciences, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK ²Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK

³Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

⁴Jane Symons Media, London

⁵Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

⁶NIHR Maudsley Biomedical Research Centre, King's College London, UK

⁷Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK

⁸National Heart and Lung Institute, Imperial College London, UK

⁹Edenfield Road Surgery, Rochdale, UK

¹⁰Salisbury District Hospital, Salisbury, UK

¹¹School of Dentistry, Institute of Clinical Sciences, University of Birmingham, Birmingham, UK

¹²Population Data Science, Swansea University Medical School, Singleton Park, Swansea, UK

¹³Centre for Public Health Research (NI), Queen's University Belfast, Belfast, UK¹⁴Usher Institute, University of Edinburgh, Edinburgh, UK

* Contributed equally

† To whom correspondence should be addressed at the Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, London E1 2AT, UK

Tel: +44 207 882 2551 | Fax: +44 207 882 2552 | Email: <u>a.martineau@qmul.ac.uk</u>

Abstract

Background: Risk factors for severe COVID-19 include older age, male sex, obesity, Black or Asian ethnicity and underlying medical conditions. Whether these factors also influence susceptibility to developing COVID-19 is uncertain.

Methods: We undertook a prospective, population-based cohort study (COVIDENCE UK) from 1st May 2020 to 5th February 2021. Baseline information on potential risk factors was captured by an online questionnaire. Monthly follow-up questionnaires captured incident COVID-19. We used logistic regression models to estimate multivariable-adjusted odds ratios (aORs) for associations between potential risk factors and risk of COVID-19.

Results: We recorded 446 incident cases of COVID-19 in 15,227 participants (2.9%). Increased risk of developing COVID-19 was independently associated with Asian/Asian British *vs.* White ethnicity (aOR 2.28, 95% CI 1.33-3.91), household overcrowding (aOR per additional 0.5 people/bedroom 1.26, 1.11-1.43), any *vs.* no visits to/from other households in previous week (aOR 1.31, 1.06-1.62), number of visits to indoor public places (aOR per extra visit per week 1.05, 1.01-1.09), frontline occupation excluding health/social care *vs.* no frontline occupation (aOR 1.49, 1.12-1.98), and raised body mass index (BMI) (aOR 1.50 [1.19-1.89] for BMI 25.0-30.0 kg/m² and 1.39 [1.06-1.84] for BMI >30.0 kg/m² *vs.* BMI <25.0 kg/m²). Atopic disease was independently associated with decreased risk (aOR 0.75, 0.59-0.97). No independent associations were seen for age, sex, other medical conditions, diet, or micronutrient supplement use.

Conclusions: After rigorous adjustment for factors influencing exposure to SARS-CoV-2, Asian/Asian British ethnicity and raised BMI were associated with increased risk of developing COVID-19, while atopic disease was associated with decreased risk.

Funding: Barts Charity, Health Data Research UK

• What is the key question?

How do demographic, socio-economic, lifestyle, dietary, pharmacological and comorbidity factors relate to the risk of developing COVID-19 in the general adult population of the UK?

• What is the bottom line?

After rigorous adjustment for factors influencing exposure to SARS-CoV-2, Asian/Asian British ethnicity and raised body mass index were associated with increased risk of developing COVID-19, while atopic disease was associated with decreased risk; no associations were seen for age, sex, or other underlying medical conditions.

• Why read on?

This large, population-based prospective study shows that there is limited overlap between risk factors for developing COVID-19 vs. those for intensive care unit admission and death as reported in hospitalised cohorts.

Introduction

COVID-19 has taken a heavy toll on the health of populations globally.¹⁻³ Risk factors for severe and fatal disease are well-recognised, and include male sex, Black or Asian ethnic origin, obesity, deprivation and a range of comorbidities including diabetes mellitus, cardiovascular disease, chronic obstructive pulmonary disease (COPD) and hypertension.^{4,5} Characterisation of risks for milder disease has been relatively neglected, but is important, both from a public health perspective (since it drives transmission to individuals at risk of severe disease), and from a biological perspective (since understanding susceptibility factors can provide insights into pathogenesis).

There is growing evidence from population-based studies to suggest that at least some risk factors for developing COVID-19 - irrespective of severity - may be distinct from those which predispose to disease at the most severe end of the spectrum. For example, population-based studies in both the US and the UK have reported that risk of COVID-19 is higher in younger vs. older adults ⁶, a finding supported by serology studies in the UK and Switzerland reporting higher prevalence of antibodies to SARS-CoV-2 in younger vs older adults.^{7,8} Again, in contrast to studies reporting that diabetes, heart disease and hypertension are risk factors for severe disease, the presence of pre-existing health conditions has been reported to associate with decreased, rather than increased, risk of SARS-CoV-2 sero-positivity in a population-based study conducted in the UK.⁷

These apparently paradoxical associations are potentially attributable to changes in behaviour in response to the pandemic, whereby people at greater risk of severe disease because of older age or presence of comorbidities may reduce social contact and visits to indoor public places in order to reduce their exposure to SARS-CoV-2. However, to our knowledge, studies to investigate whether behaviours influencing risk of such exposure might partly explain associations between older age, presence of comorbidities and lower risk of developing COVID-19 are lacking. Such studies could potentially shed light on other controversies relating to risk factors for developing COVID-19, such as the extent to which ethnic differences in disease susceptibility can be explained by behavioural, occupational and socio-

economic factors,⁹ and whether lifestyle, diet, and use of micronutrient supplements may influence risk of developing COVID-19.^{10,11}

In order to address this knowledge gap, we established a new longitudinal study (COVIDENCE UK) at the start of the pandemic, with the specific aim of capturing detailed information on a very wide range of potential risk factors for COVID-19. Sufficient incident cases of test-confirmed COVID-19 have now accumulated to allow us to evaluate how a comprehensive panel of demographic, socio-economic, lifestyle, dietary, pharmacological and comorbidity factors relate to the risk of developing COVID-19.

Methods

Study design, setting and participants

COVIDENCE UK (Longitudinal population-based observational study of coronavirus disease in the UK population, www.qmul.ac.uk/covidence) is a prospective cohort study with four main objectives, namely to: i) determine risk factors for incident COVID-19 in the UK population; ii) characterise the natural history of COVID-19 in the UK population; iii) evaluate the impact of COVID-19 on the physical and mental health of the UK population; and iv) provide a resource from which to identify potential participants for future clinical trials of interventions to reduce incidence and/or severity of COVID-19 and other acute respiratory infections. Inclusion criteria were age 16 years or more and residence in the UK at the point of enrolment; there were no exclusion criteria. Participants were invited via a national media campaign to complete an on-line baseline questionnaire to capture information on potential symptoms of COVID-19 experienced since 1st February 2020, results of any COVID-19 tests, and details of a wide range of potential risk factors for COVID-19, as described below. Follow-up questionnaires were administered at monthly intervals to capture incident test-confirmed COVID-19 as well as potential symptoms of COVID-19. The study was launched on 1st May 2020, and this paper reports findings of analysis of data collected up to 5th February 2021.

Sponsorship, registration, ethics and reporting

The study was sponsored by Queen Mary University of London and approved by Leicester South Research Ethics Committee (ref 20/EM/0117). It is registered with ClinicalTrials.gov (NCT04330599).

Outcomes

The primary outcome was incidence of test-confirmed COVID-19, as defined by a selfreported positive result from PCR or lateral flow testing of eluate from a nose or throat swab for SARS-CoV-2. Those who were not tested were assumed to be test negative. The secondary outcome was incidence of symptom-defined probable COVID-19, with casehood defined using the algorithm described by Menni and colleagues,¹² based on age, sex and self-reported loss of smell/taste, significant/severe persistent cough, severe fatigue and skipped meals (see supplementary Appendix for further details). This outcome was included in order to address potential under-ascertainment of COVID-19 arising from use of test-confirmed COVID-19 as an outcome measure, which would not have captured episodes where testing was not done, potentially introducing collider bias.¹³ Test-confirmed COVID-19 and symptom-defined probable COVID-19 were analysed as separate outcomes (i.e. they were not combined). In order to minimise the potential for reverse causality to explain associations observed, outcomes occurring within 30 days of enrolment were excluded. At enrolment, participants were asked to provide details of potential symptoms of COVID-19 experienced since 1st February 2020, and results of any PCR or lateral flow tests for SARS-CoV-2 performed on eluates from nose / throat swabs to date.

Independent variables

At enrolment, participants were asked to complete an on-line questionnaire capturing information about their socio-demographic characteristics, type of occupation, lifestyle, weight, height, longstanding medical conditions, medication use, vaccination status, diet and supplemental micronutrient intake (for baseline questionnaire, see Table S1, Supplementary Appendix). Monthly on-line follow-up questionnaires (Table

S2, Supplementary Appendix) captured incident test-confirmed COVID-19 and potential symptoms of COVID-19.

Sample size

The sample size required to detect an odds ratio of at least 1.08 (effect size) for a binary exposure variable with maximum variability (probability = 0.50 changing to 0.52) and correlated with other variables in the model (R^2 = 0.5), with a power of 90% using a one-sided test with 5% significance level was estimated as 10,721, using the 'powerlog' program in Stata 14.2 (College Station, TX). Assuming 10% censoring at baseline (prevalent COVID-19 and missing) and 20% loss to follow-up, we aimed to recruit a minimum of 14,890 participants. No upper limit for sample size was specified.

Statistical methods

Statistical analyses were performed using Stata 14.2. Putative risk factors for COVID-19 were selected *a priori* and classified into the following groups: socio-demographic, occupational and lifestyle factors; longstanding medical conditions, medication use and vaccination status; and diet and supplemental micronutrient intake. To produce patient-level covariates for each class of medications investigated, participant answers were mapped to drug classes listed on the British National Formulary (BNF) or the DrugBank and Electronic Medicines Compendium databases if not explicitly listed on the BNF; further details of the computational methods used to achieve this are presented in supplementary Appendix. Index of Multiple Deprivation (IMD) 2019 scores were assigned according to participants' postcodes, and categorised into quartiles.

Participants who reported definite COVID-19 prior to enrolment, or who were classified as having had symptom-defined probable COVID-19 prior to enrolment on the basis of self-reported symptoms, were excluded from prospective analyses. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for each individual factor, first in a crude model, then in 'minimally adjusted' models. For the primary outcome of test-confirmed COVID-19, the minimally adjusted model included age (six categories), sex (male/female), duration of participation and frequency of COVID-19 testing. For the secondary outcome of symptom-defined probable COVID-19, the minimally adjusted model included age (six categories), sex and duration of participation only. Factors associating independently with each outcome at the 10% significance level were evaluated for collinearity using Cramer's V statistic¹⁴ for all pairwise combinations of the covariates and clustering with average-linkage hierarchical clustering using 1 - V as a dissimilarity metric. The resultant heat-maps were reviewed, and where a cluster of highly correlated covariates was identified, one variable within each cluster that was deemed to relate most closely and plausibly to COVID-19 risk was selected for inclusion in the multivariable model. Age was included within the multivariable model regardless of collinearity, since all covariates investigated in the collinearity analysis exhibited a significant relationship with COVID-19 in the minimally-adjusted model that controlled for age. Variables that did not exhibit clustering in the heat-maps were all included in the final model, along with age, sex, IMD score quartile, duration of participation and frequency of COVID-19 testing. We also used restricted cubic spline analysis to examine the shape of relationships between BMI and age and incident test-defined COVID-19 in multivariable-adjusted models. We selected the number of knots based on the values of Akaike information criteria (AIC) to fit the best-approximating model, chose the first knot as reference (at 20.7 kg/m² and 32.4 years, respectively), and tested for linearity using the Wald test. The lowest AIC (i.e. the best-fitting model) was obtained by 3 knots for BMI and 5 knots for age. Correction for multiple comparisons was not applied, on the grounds that we were testing *a priori* hypotheses for all risk factors investigated.¹⁵ We conducted sensitivity analysis for unmeasured confounding by estimating E-values¹⁶ using the 'evalue' package in Stata.¹⁷ Two other sensitivity analyses were also performed: one excluded participants who received one or more doses of COVID-19 vaccine, and the other excluded those who were randomised to receive vitamin D supplementation as part of a nested clinical trial that was initiated during follow-up. We also performed an exploratory analysis to determine whether COVID-19 risk differed for participants with atopic vs. non-atopic asthma endotypes; this was conducted on the basis of evidence suggesting that decreased expression of ACE2, the gene encoding the SARS-CoV-2 receptor, has been reported in people with asthma who have high levels of allergic sensitisation.¹⁸

Role of the funding source

Barts Charity and Health Data Research UK had no role in study design, data analysis, data interpretation, or writing of the report. MT, HH and MG had access to raw data. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.

Results

Of the 17,558 participants who completed the COVIDENCE UK baseline questionnaire on or before 2nd November 2020, we excluded those who were identified as already having had test-confirmed and/or symptom-defined probable COVID-19 (n=1,477). Of the remaining 16,081 participants, 15,227 completed at least one subsequent monthly follow-up questionnaire at least 30 days after enrolment and were included in this prospective analysis; 14,348 completed the final follow-up questionnaire on or before 5th February 2021, giving a retention rate of 89.2% (Figure S1, Supplementary Appendix). Selected baseline characteristics of participants included in the prospective analysis are presented in Table 1; their characteristics are compared with those who were excluded from this analysis in Table S3, Supplementary Appendix. Mean age of those contributing data to prospective analyses was 59.4 years (range 16.0 to 94.4 years), 69.8% were female, and 94.9% identified their ethnic origin as White. The geographical distribution of COVIDENCE UK participants aligned closely with that of incident COVID-19 in the UK (Figure S2, Supplementary Appendix).

A total of 446 participants experienced at least one episode of PCR- or lateral flow test-confirmed COVID-19 during 2,613,921 person-days of follow-up, of whom 32 were hospitalised. We calculated crude and minimally-adjusted ORs for associations between risk of test-confirmed COVID-19 and socio-demographic, occupational and lifestyle factors (Table 2); longstanding conditions, medication use and vaccination status (Table 3); and diet and supplemental micronutrient intake (Table 4). After adjustment for age, sex, duration of participation and testing frequency ('minimal adjustment'), the following factors were found to associate with increased risk of

COVID-19 with P <0.10: Asian / Asian British vs. White ethnic origin, housing type (paying mortgage and 'other' vs. owning own home), frontline vs. non-frontline worker status, household overcrowding (>0.5 vs. ≤0.5 people per bedroom), any visit vs. no visits to/from other households in the previous week, presence vs. absence of schoolchildren and working-age adults in the household, living with others vs. living alone, periodontitis, having vs. not having a dog at home, any vs. no travel to work or place of study in the week preceding questionnaire completion, number of visits to shops or other indoor public places per week (quartiles 2,3,4 vs quartile 1), alcohol consumption (15-21 vs 0 U/week); sleep duration (7 or \geq 9 vs 8 hours per night); raised body mass index (BMI) (>25.0 vs \leq 25.0 kg/m²) and history vs. no history of BCG vaccination. The following factors associated with decreased risk of COVID-19 with P<0.10 after minimal adjustment: age ≥60 vs. 16-29.99 years, education to college or postgraduate level vs primary / secondary level, shielding vs. non-shielding, lowimpact physical activity (≥2 vs 0 hours/week), presence vs. absence of asthma diagnosis, presence vs. absence of atopic disease (defined by atopic eczema/dermatitis and/or hayfever/allergic rhinitis), use vs. no use of systemic immunosuppressants, inhaled corticosteroids and bronchodilators (defined as β-2adrenoreceptor agonists or anticholinergics), higher intake of fruit and vegetables (top vs bottom quartiles) and use vs. no use of vitamin D supplements.

All factors associating with test-confirmed COVID-19 with P <0.10 in the minimallyadjusted model were then assessed for collinearity: the resultant heat-map (Figure S3, Supplementary Appendix) revealed a high degree of collinearity between the number of working-age adults in the household, multi-generational households and number of people per bedroom. Since household over-crowding (as indicated by number of people per bedroom) was deemed to relate most closely to SARS-CoV-2 exposure risk from a clinical / epidemiological perspective, the other two independent variables were excluded from the multivariable model.

Table 5 presents fully-adjusted ORs for associations between potential risk factors for test-confirmed COVID-19. The final multivariable model adjusted mutually for age, sex, duration of participation, test frequency, ethnicity, highest educational level attained, IMD rank, household income, housing type, number of people per bedroom, presence of schoolchildren at home, presence of a dog in the household, shielding,

visits to/from other households, visits to shops and other indoor places, travel to work or study, frontline worker status, low-impact physical activity, alcohol intake, BMI, history of asthma, history of atopic disease, use of systemic immunosuppressants, use of inhaled corticosteroids, use of bronchodilators, BCG vaccination status, intake of fruit, vegetables and salads, and intake of supplemental vitamin D. Increased risk of developing COVID-19 was independently associated with Asian/Asian British vs. White ethnicity (aOR 2.28, 95% CI 1.33-3.91), household overcrowding (aOR per additional 0.5 people/bedroom 1.26, 1.11-1.43), any vs. no visits to/from other households in previous week (aOR 1.31, 1.06-1.62), number of visits to indoor public places (aOR per extra visit per week 1.05, 1.01-1.09), frontline occupation outside health/social care vs. no frontline occupation (aOR 1.49, 1.12-1.98), and raised BMI (aOR 1.50 [1.19-1.89] for BMI 25.0-30.0 kg/m² and 1.39 [1.06-1.84] for BMI >30.0 kg/m² vs. BMI <25.0 kg/m²). Lower risk of test-confirmed COVID-19 was independently associated with history of atopic disease (aOR 0.75, 0.59-0.97) and taking systemic immunosuppressants (aOR 0.47, 0.22-0.99). Restricted cubic spline analysis showed non-linear associations between BMI (P for non-linearity 0.009) and age (P for non-linearity 0.02) and incident test-defined COVID-19 (Figure 1).

We performed two sensitivity analyses to explore the robustness of the multivariable results. The first (Table S⁴, Supplementary Appendix) excluded 3,202 participants who received one or more doses of COVID-19 vaccine before the date of the data download (5th February 2021). The second (Table S⁵, Supplementary Appendix) excluded 3,813 participants who commenced vitamin D supplements after enrolment in the cohort due to participation in a clinical trial. Both analyses yielded similar findings to those presented above. An exploratory analysis to determine whether COVID-19 risk differed for participants with atopic vs. non-atopic asthma endotypes (as defined by the presence or absence of atopic eczema/dermatitis and/or hayfever/allergic rhinitis) showed a reduced risk of COVID-19 for participants with atopic asthma (aOR 0.62, 0.41-0.93), but not for those with non-atopic asthma (aOR 0.88, 0.60-1.30), as compared to participants without atopic disease or asthma. These effect estimates did not materially change after further adjustment for inhaled corticosteroids (Table S⁶, Supplementary Appendix).

We then proceeded to investigate determinants of symptom-defined probable COVID-19, with casehood ascribed using an algorithm published by Menni et al.¹² In the subset of 6,035 COVIDENCE UK participants entering the prospective analysis who had one or more tests for COVID-19 during the follow-up period, this case definition had sensitivity and specificity for test-confirmed COVID-19 of 0.47 and 0.97, respectively, with an area under the receiver operating characteristic curve of 0.72 (95% CI, 0.69 to 0.74; Table S7, Supplementary Appendix). Potential risk factors associating with probable symptom-defined COVID-19 with P<0.10 in a minimally-adjusted model (i.e. adjusting for age, sex and duration of participation) were included in the multivariable model presented in Table S⁸, Supplementary Appendix. Increased risk of probable symptom-defined COVID-19 was independently associated with Asian / Asian British vs. White ethnicity, housing type (having a mortgage vs. homeownership), household overcrowding (>1.0 vs. ≤ 0.5 people per bedroom), health or social care occupation, use of cod liver oil supplements, poorer self-assessed general health, periodontitis and use of selective serotonin reuptake inhibitors, while lower risk of probable symptom-defined COVID-19 was independently associated with greater age (age ≥ 50 vs. 16-29.99 years).

Discussion

In this large, prospective population-based study evaluating a diverse array of potential risk factors for developing COVID-19, we found that Asian/Asian British ethnicity, household overcrowding, indoor social mixing, employment as a frontline worker outside of health and social care, and being overweight or obese were all independently associated with an increased risk of test-confirmed COVID-19. Associations with household overcrowding and visits to indoor public places showed dose-response relationships, strengthening causal inference. History of atopic disease and use of systemic immunosuppressant medication were independently associated with decreased risk of test-positive disease. No statistically significant independent associations with disease risk were seen for other factors investigated, including age, sex, diet, supplemental micronutrient intake, and other longstanding conditions and medications.

This study sheds new light on the degree of overlap between risk factors for developing COVID-19 (irrespective of severity) *vs.* risk factors for developing severe or fatal disease specifically. Our finding that people of Asian/Asian British ethnic origin are at

increased risk of developing COVID-19 is consistent with reports of increased susceptibility and disease severity in this group.^{4,7,19} One limitation of previous studies investigating ethnic variation in COVID-19 risk is that they did not adjust for behaviours influencing SARS-CoV-2 exposure, such as visits to other households and indoor public places. In our study, increased risk of developing COVID-19 in people of Asian/Asian British ethnic origin was not explained by such behaviours, nor by social deprivation, domestic overcrowding, occupation, BMI, or comorbidities. There is therefore an urgent need for further research to investigate social and biological factors that might explain ethnic disparities in risk of developing COVID-19, including vitamin D deficiency.⁹ The association between raised BMI and increased susceptibility to COVID-19 that we found is consistent with studies identifying obesity as a risk factor for both susceptibility to, and severe outcomes of, COVID-19.^{4,20,21} It would appear that immune dysregulation associated with obesity may increase susceptibility to infection as well as disease severity.

By contrast, a number of established risk factors for severe and fatal disease, including older age, male sex and underlying conditions such as diabetes, heart disease, COPD and hypertension, were not associated with risk of developing COVID-19 in our study, where cases were predominantly mild (93.1% non-hospitalised). Our finding of no association between kidney disease and susceptibility to COVID-19 contrasts with that of de Lusignan and colleagues,²² who reported such an association in a study that was conducted earlier in the UK pandemic when testing was limited to those with more severe COVID-19 illness presenting to hospital. The bias resulting from focusing testing on more severe disease in that study may have contributed to the different findings in our study, which was conducted over a later period when testing was more widely available. In contrast with other studies,^{23,24} we found no association between intake of micronutrient supplements and protection against COVID-19: this may reflect a false-negative result from our study (arising due to a relative lack of power to detect modest protective effects), or a false-positive result from other studies arising as a result of less rigorous adjustment for potential socio-economic confounding.

We also In keeping with reports from the UK⁷ and elsewhere,⁸ we found younger age to be associated with increased risk of developing COVID-19 in crude and minimallyadjusted models. However, this association did not persist after adjustment for multiple potential confounders, including behaviours related to social mixing, suggesting that lower incidence of COVID-19 in older adults in our study may be explained by reductions in social contact. We did not see a difference in disease risk for people with diabetes, heart disease or hypertension. Whilst this contrasts with a study reporting lower prevalence of SARS-CoV-2 seropositivity among people with these underlying conditions, that study did not adjust, as we did, for behaviours influencing exposure to infection.⁷ The only long-standing conditions associated with disease risk in our study were atopic diseases, which were associated with reduced risk of disease, particularly among those who also had asthma. This may reflect decreased expression of *ACE2*, the gene encoding the SARS-CoV-2 receptor, which has been reported in people with both high levels of allergic sensitisation and asthma.¹⁸

Our study has several strengths. COVIDENCE UK was set up with the specific purpose of investigating incident COVID-19, and consequently our questionnaires were specifically designed to capture contemporaneous and granular detail on potential risk factors, including behaviours influencing risk of exposure to SARS-CoV-2. Our finding that visits to other households and indoor public places were associated with increased risk of disease supports the case for restricting such activities as a public health strategy to control disease. Our low rates of loss to follow-up reflect the very high degree of participant engagement with the COVIDENCE UK study. Our ability to identify episodes of milder disease affords potential insights into susceptibility factors as well as severity factors, and sets our study apart from long-established cohort studies in which assessment of risk factors may be temporally remote, and capture of outcomes is limited to events that are fatal or that precipitate hospitalisation. Our prospective design, coupled with censoring events occurring within 30 days of enrolment minimises the potential for reverse causation to explain associations observed.

Our study also has limitations. Use of test-confirmed COVID-19 as our primary outcome may have resulted in under-ascertainment of disease, particularly early in the pandemic (when testing capacity was particularly limited) and among people with less access to testing services; this might introduce collider bias.¹³ We addressed this

limitation by including a secondary outcome of symptom-defined probable COVID-19, which did not rely on access to testing. However, the lack of direct swabbing surveillance and reliance on results of routine testing that will usually have been prompted by incident symptoms may have led to under-ascertainment of asymptomatic SARS-CoV-2 infection. A second issue relates to the self-selected nature of the cohort participants. Ethnic minorities, particularly people of Black, African and Caribbean ethnic origin, were under-represented in the study; a lack of statistical power may explain why we did not confirm an increased risk of disease in these groups. People with limited internet access or with fewer digital skills are also less likely to have participated. However, lack of representativeness in a study population does not preclude identification of causal associations.²⁵ Third, as with any observational study, we cannot exclude the possibility that the associations we report may be explained by residual and/or unmeasured confounding. We sought to minimise this by capture of, and mutual adjustment for, a comprehensive panel of potential confounders. Calculation of E-values enabled us to determine how likely it was that our main findings might be 'explained away' by unmeasured/unknown confounding factors. For example, for an unknown confounder to fully explain the association between frequent visits to shops/indoor places and COVID-19 risk (OR 2.63 comparing top versus bottom quartile of exposure), it would need to be associated with both the outcome and the exposure (above and beyond the measured confounders) by an odds ratio of nearly 5 or more (Table 5); weaker confounding could not explain away the association. In contrast, for the association between >9 hours sleep and COVID-19 risk (OR 1.29) to be explained away, an unknown confounder would need to be associated with the exposure and outcome by an odds ratio of at least 1.90; this effect estimate is comparable to other risk factor associations we have found, hence, more plausible for an unknown confounder. Accordingly, evidence for an unconfounded, causal association is considerably stronger for frequent visits to shops/indoor places than it is for prolonged sleep duration.

In conclusion, this population-based longitudinal study conducted in UK adults found that increased risk of developing COVID-19 associated independently with Asian/Asian British ethnicity, household overcrowding, visits to other households and other indoor public places, frontline occupation outside of health or social care, and increased BMI, after rigorous adjustment for multiple confounders. Atopic diseases, and especially atopic asthma, were associated with decreased risk. In contrast to studies investigating risk factors for severe disease, older age, male sex and other comorbidities were not associated with increased risk of developing COVID-19.

Acknowledgements

This study was supported by a grant from Barts Charity to ARM and CJG (ref MGU0466). The work was carried out with the support of BREATHE - The Health Data Research Hub for Respiratory Health [MC_PC_19004] in partnership with SAIL Databank. BREATHE is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. MT is supported by a grant from the Rosetrees Trust and The Bloom Foundation (ref: M771). The views expressed are those of the authors and not necessarily those of Barts Charity, BREATHE or Health Data Research UK. We thank all the people who participated in the COVIDENCE UK study, and the following organisations who supported study recruitment: Asthma UK, the British Heart Foundation, the British Lung Foundation, the British Obesity Society, Cancer Research UK, Diabetes UK, Future Publishing Ltd, Kidney Care UK, Kidney Wales, Mumsnet, the National Kidney Federation, the National Rheumatoid Arthritis Society, the North West London Health Research Register (DISCOVER), Primary Immunodeficiency UK, the Race Equality Foundation, SWM Health Ltd, the Terence Higgins Trust and Vasculitis UK.

Author Contributions

ARM wrote the study protocol, with input from HH, MT, CR, GB and SOS. HH, MT, JS, CR, KY, MD, KT, SF, SI, AM, PP, GL-J, TD, IC, DM, GD, RL, CJG, FK, AS, GB, SAS and ARM contributed to questionnaire development and design. HH co-ordinated and managed the study, with input from ARM, MT, JS and SOS. HH, JS, ARM, SOS, NSH and BA supported recruitment. HH, MT, MG, MD, KT, SSR, AAK, SER, PJL and DAJ contributed to data management and coding medication data. Statistical analyses were done by MT, with input from SOS, ARM, MG and HH. ARM wrote the first draft of the report. All authors revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

Transparency Declaration

ARM is the manuscript's guarantor and he affirms that this is an honest, accurate, and transparent account of the study.

	Total	Test-confirmed COVID-19		
	-	No Yes		
n (%)	15227 (86.7)	<mark>14781 (97.1)</mark>	<mark>446 (2.9)</mark>	
Age, n (%)				
16-29.99 y	576 (3.8)	<mark>550 (3.7)</mark>	<mark>26 (5.8)</mark>	
30-39.99 y	988 (6.5)	<mark>941 (6.4)</mark>	<mark>47 (10.5)</mark>	
40-49.99 y	1787 (11.7)	<mark>1693 (11.5)</mark>	<mark>94 (21.1)</mark>	
50-59.99 y	3361 (22.1)	<mark>3226 (21.8)</mark>	<mark>135 (30.3</mark>)	
60-69.99 y	5105 (33.5)	<mark>5008 (33.9)</mark>	<mark>97 (21.7)</mark>	
≥70.00 y	3410 (22.4)	<mark>3363 (22.8)</mark>	<mark>47 (10.5)</mark>	
Age, y	59.4 ± 13.4	<mark>59.5 ± 13.4</mark>	<mark>53.3 ± 13.</mark> 2	
Sex, n (%)				
Female	10630 (69.8)	10301 (69.7)	<mark>329 (73.8</mark>)	
Male	4597 (30.2)	<mark>4480 (30.3)</mark>	<mark>117 (26.2)</mark>	
Ethnicity, n (%)				
White	14449 (94.9)	14046 (95.0)	<mark>403 (90.4)</mark>	
Mixed/Multiple/Other ethnic groups	401 (2.6)	382 (2.6)	<mark>19 (4.3)</mark>	
South Asian	281 (1.8)	263 (1.8)	18 (4.0)	
Black/African/Caribbean/Black British	96 (0.6)	90 (0.6)	<mark>6 (1.3)</mark>	
Country of residence, n (%)			<u> </u>	
England	13463 (88.4)	13052 (88.3)	<mark>411 (92.2)</mark>	
Northern Ireland	294 (1.9)	281 (1.9)	13 (2.9)	
Scotland	915 (6.0)	910 (6.2)	5 (1.1)	
Wales	. ,			
Household income sufficient for basic	555 (3.6)	<mark>538 (3.6)</mark>	<mark>17 (3.8)</mark>	
needs, n (%)				
Yes	14209 (93.3)	13793 (93.3)	<mark>416 (93.3</mark>)	
Mostly / Sometimes / No	1016 (6.7)	986 (6.7)	30 (6.7)	
Housing, n (%)				
Owns own home	9326 (61.3)	9137 (61.8)	189 (42.4)	
Mortgage	3743 (24.6)	3570 (24.2)	173 (38.8)	
	1069 (7.0)	1029 (7.0)	40 (9.0)	
Privately Renting	477 (3.1)			
Renting from council Others		461 (3.1)	16 (3.6)	
	610 (4.0)	<mark>582 (3.9)</mark>	<mark>28 (6.3)</mark>	
Number of people per bedroom, n (%)	5000 (00.0)	5700 (00 A)		
≤0.50	5836 (38.6)	5738 (39.1)	98 (22.3)	
>0.50-0.99	4179 (27.6)	4069 (27.7)	<mark>110 (25.0</mark>)	
1.00-1.99	4766 (31.5)	<mark>4553 (31.0)</mark>	<mark>213 (48.4</mark>)	
≥2.00	333 (2.2)	<mark>314 (2.1)</mark>	<mark>19 (4.3)</mark>	
Highest educational level attained, n (%)				
Primary/Secondary	1649 (10.8)	<mark>1598 (10.8)</mark>	<mark>51 (11.4)</mark>	
Higher/further (A levels)	2233 (14.7)	<mark>2164 (14.7)</mark>	<mark>69 (15.5)</mark>	
College	6720 (44.2)	<mark>6523 (44.2)</mark>	197 (44.2)	
Post-graduate	4610 (30.3)	<mark>4481 (30.3)</mark>	129 (28.9)	
Occupational status, n (%)				
Employed	5349 (35.1)	<mark>5091 (34.4)</mark>	<mark>258 (57.8</mark>)	
Self-employed	1369 (9.0)	1330 (9.0)	<mark>39 (8.7)</mark>	
Retired	6951 (45.6)	6856 (46.4)	<mark>95 (21.3)</mark>	
Furloughed	365 (2.4)	348 (2.4)	17 (3.8)	
Unemployed	267 (1.8)	254 (1.7)	13 (2.9)	
Other	926 (6.1)	902 (6.1)	24 (5.4)	
Frontline worker, n (%)		()	<u> </u>	
No	12474 (82.0)	12198 (82.6)	<mark>276 (61.9)</mark>	
Other frontline worker	1572 (10.3)	1492 (10.1)	80 (17.9)	
Health or social care worker				
	1167 (7.7)	<mark>1077 (7.3)</mark>	<mark>90 (20.2)</mark>	
Body mass index, n (%)	7424 (40.0)	7054 (40.0)	177 (00.0)	
<25, kg/m2	7431 (48.9)	7254 (49.2)	177 (39.8)	
25-30, kg/m2	4829 (31.8)	4661 (31.6)	168 (37.8)	
>30, kg/m2	2929 (19.3)	<mark>2829 (19.2)</mark>	100 (22.5)	

Table 1. Selected cohort characteristics

E	0074 (00.0)		
Excellent	3071 (20.2)	2982 (20.2)	89 (20.0)
Very good	6024 (39.6)	<u>5850 (39.6)</u>	<mark>174 (39.0</mark>)
Good	4048 (26.6)	<mark>3928 (26.6)</mark>	<mark>120 (26.9)</mark>
Fair	1633 (10.7)	<mark>1581 (10.7)</mark>	<mark>52 (11.7)</mark>
Poor	449 (2.9)	<mark>438 (3.0)</mark>	<mark>11 (2.5)</mark>
Tobacco smoking history, n (%)			
Never-smoker	8529 (56.0)	<mark>8282 (56.0)</mark>	<mark>247 (55.4)</mark>
Ex-smoker	5862 (38.5)	<mark>5697 (38.5)</mark>	<mark>165 (37.0)</mark>
Current smoker	836 (5.5)	<mark>802 (5.4)</mark>	<mark>34 (7.6)</mark>
Alcohol consumption in week prior to			
questionnaire completion, n (%)			
None	4271 (28.1)	<mark>4152 (28.1)</mark>	<mark>119 (26.7)</mark>
1-7 units	5406 (35.5)	<mark>5244 (35.5)</mark>	<mark>162 (36.3)</mark>
8-14 units	2961 (19.4)	<mark>2876 (19.5)</mark>	<mark>85 (19.1)</mark>
15-21 units	1417 (9.3)	<mark>1366 (9.2)</mark>	<mark>51 (11.4)</mark>
22-28 units	657 (4.3)	<mark>640 (4.3)</mark>	<mark>17 (3.8)</mark>
>28 units	513 (3.4)	501 (3.4)	12 (2.7)
COVID-19 vaccine during follow-up, n (%)			
No	<mark>14529 (85.7)</mark>	<mark>12675 (85.8)</mark>	<mark>365 (81.8)</mark>
Yes	<mark>2416 (14.3)</mark>	2106 (14.2)	81 (18.2)

		Number (%) with incident test-confirmed COVID-19	Total number	Crude odds ratio (95% Cl)	Minimally adjusted odd ratio (95% Cl) ¹
	16-29.99	26 (4.5)		1.00	1.00
	30-39.99	47 (4.8)	-	1.06 (0.65-1.73)	1.08 (0.65-1.78)
Age, years	40-49.99	94 (5.3)	15227	1.17 (0.75-1.83)	1.24 (0.79-1.95)
	50-59.99	135 (4.0)	-	0.89 (0.58-1.36)	0.96 (0.62-1.49)
	60-69.99	97 (1.9)	-	0.41 (0.26-0.64)	0.49 (0.31-0.77)
	≥70.00	47 (1.4)		0.30 (0.18-0.48)	0.39 (0.24-0.64)
Sex	Female Male	329 (3.1) 117 (2.5)	15227	<u>1.00</u> 0.82 (0.66-1.01)	<u>1.00</u> 1.08 (0.86-1.34)
	Asian/Asian British	18 (6.4)		2.39 (1.46-3.88)	1.99 (1.20-3.30)
	Black/African/Caribbean/B		-		
	lack British	6 (6.3)		2.32 (1.01-5.34)	1.98 (0.84-4.65)
Ethnicity	Mixed/Multiple/other	40 (4 7)	- 15227	4 70 (4 00 0 70)	4 40 (0 00 0 00)
	ethnic groups	19 (4.7)		1.73 (1.08-2.78)	1.40 (0.86-2.28)
	White	403 (2.8)	-	1.00	1.00
	Primary/Secondary	51 (3.1)		1.00	1.00
Highest advectional level attained	Higher/further (A levels)	69 (3.1)	15010	1.00 (0.69-1.44)	0.86 (0.59-1.25)
Highest educational level attained	College	197 (2.9)	15212	0.95 (0.69-1.29)	0.75 (0.54-1.03)
	Post-graduate	129 (2.8)		0.90 (0.65-1.25)	0.62 (0.44-0.87)
	Q1 (most deprived)	131 (3.6)	-	1.30 (1.01-1.69)	1.22 (0.93-1.60)
Index of multiple deprivation (IMD)	Q2	108 (2.8)	15152	1.02 (0.78-1.34)	0.97 (0.73-1.28)
rank, quartiles	Q3	97 (2.5)		0.90 (0.68-1.19)	0.89 (0.67-1.19)
	Q4 (least deprived)	107 (2.8)		1.00	1.00
Household income sufficient for basic	Yes	416 (2.9)	15225	1.00	1.00
needs	Mostly / Sometimes / No	30 (3.0)		1.01 (0.69-1.47)	0.85 (0.58-1.25)
Claiming universal credit	No	425 (2.9)	15178	1.00	1.00
5	Yes	19 (4.7)		1.65 (1.03-2.64)	1.25 (0.77-2.03)
	Owns own home	189 (2.0)	15005	1.00	1.00
Lesse in m	Mortgage	173 (4.6)		2.34 (1.90-2.89)	1.34 (1.04-1.74)
Housing	Privately Renting Renting from council	40 (3.7) 16 (3.4)	15225	<u>1.88 (1.33-2.66)</u> 1.68 (1.00-2.82)	<u>1.17 (0.79-1.73)</u> 1.20 (0.70-2.07)
	Others	28 (4.6)	-	2.33 (1.55-3.49)	1.54 (0.95-2.49)
	No	276 (2.2)		1.00	1.00
	Health or social care		-		
Frontline worker	worker	90 (7.7)	15213	3.69 (2.89-4.72)	1.68 (1.28-2.21)
	Other frontline worker	80 (5.1)	-	2.37 (1.84-3.06)	1.85 (1.42-2.42)
Chieldin a	No	423 (3 0)	45474	1.00	1.00
Shielding	Yes	23 (2.0)	- 15171	0.64 (0.42-0.98)	0.63 (0.41-0.97)
	≥0.50	98 (1.7)		1.00	1.00
Number of people per bedroom	>0.50-0.99	110 (2.6)	15114	1.58 (1.20-2.08)	1.34 (1.01-1.78)
	1-1.99	213 (4.5)	13114	2.74 (2.15-3.49)	1.91 (1.46-2.50)
	≥2.00	19 (5.7)		3.54 (2.14-5.87)	2.41 (1.40-4.13)
Any visits to/from other households in	No	202 (2.7)		1.00	1.00
week prior to questionnaire completion	Yes	244 (3.2)	15217	1.21 (1.00-1.46)	1.46 (1.19-1.80)
Pre-school children (0-4 years old) at	No	416 (2.8)	- 15191	1.00	1.00
home with participant	Yes	30 (5.9)		2.15 (1.47-3.15)	1.19 (0.77-1.84)
Schoolchildren (5-15 years old) at	No	351 (2.6)	- 15182	1.00	1.00
home with participant	Yes	95 (5.5)	-	2.18 (1.73-2.75)	1.42 (1.08-1.87)
Working-age adult (16-64 years old)	No	117 (1.6)	15183	1.00	1.00
at home with participant	Yes	329 (4.2)		2.74 (2.21-3.39)	1.86 (1.45-2.41)
Number of different reportions in	Living alone	46 (1.6)	-	1.00	1.00
Number of different generations in household	Single generation	230 (2.8)	15227	1.78 (1.29-2.45)	1.66 (1.19-2.30)
	Two generations Three generations	<u>164 (4.1)</u> 6 (5.0)	-	<u>2.62 (1.88-3.64)</u> 3.27 (1.37-7.83)	2.08 (1.48-2.94) 2.54 (1.04-6.23)
	No	344 (2.9)		<u> </u>	1.00
Cat at home	Yes	102 (3.1)	15215	1.06 (0.85-1.33)	0.88 (0.70-1.12)
	No	317 (2.7)		1.00 (0.05-1.55)	1.00
Dog at home	Yes	129 (3.6)	15215	1.33 (1.08-1.64)	1.21 (0.97-1.50)
Number of public transport journeys in	0	393 (2.9)		1.00	1.00
week prior to questionnaire	1-5	35 (3.0)	15175	1.02 (0.72-1.45)	1.12 (0.78-1.61)
completion	≥6	17 (3.7)	10170	1.29 (0.79-2.12)	1.37 (0.82-2.28)
	No	37 (2.5)		1.00	1.00
Travel to work/study in week prior to	INU	37 (2.3)	- 15,042		

Table 2. Socio-demographic, occupational and lifestyle factors and risk of test-confirmed

 COVID-19: crude and minimally-adjusted odds ratios

		Number (%) with incident test-confirmed COVID-19	Total number	Crude odds ratio (95% Cl)	Minimally adjusted odd ratio (95% Cl) ¹
	Not currently working or studying	88 (1.7)		0.68 (0.46-1.00)	1.20 (0.79-1.81)
Normalis and state to a large and a the sec	Q1	33 (1.5)		1.00	1.00
Number of visits to shops and other indoor public places in week prior to	Q2	151 (3.0)	15207	2.05 (1.40-2.99)	2.23 (1.51-3.29)
questionnaire completion, quartiles	Q3	118 (3.3)	15207	2.25 (1.52-3.32)	2.77 (1.85-4.14)
questionnalle completion, quartiles	Q4	144 (3.2)	_	2.16 (1.48-3.17)	3.38 (2.25-5.07)
	Never-smoker	247 (2.9)		1.00	1.00
Tobacco smoking status	Ex-smoker	165 (2.8)	15227	0.97 (0.80-1.19)	1.09 (0.89-1.35)
-	Current smoker	34 (4.1)	_	1.42 (0.99-2.05)	1.24 (0.85-1.82)
Regular exposure to environmental	No	433 (2.9)	15226	1.00	1.00
tobacco smoke at home or in car	Yes	13 (3.9)	19220	1.35 (0.77-2.37)	1.17 (0.66-2.09)
	Never-vaper	410 (2.9)	15185	1.00	1.00
Vaping status	Ex-vaper	16 (3.2)		1.12 (0.67-1.86)	0.89 (0.53-1.50)
	Current vaper	19 (4.0)		1.40 (0.88-2.24)	1.04 (0.64-1.69)
	None	119 (2.8)	- 15225	1.00	1.00
	1-7	162 (3.0)		1.08 (0.85-1.37)	1.08 (0.85-1.38)
Alcohol consumption in week prior to	8-14	85 (2.9)		1.03 (0.78-1.37)	1.07 (0.80-1.43)
questionnaire completion, units	15-21	51 (3.6)		1.30 (0.93-1.82)	1.40 (0.99-1.98)
	22-28	17 (2.6)		0.93 (0.55-1.55)	1.10 (0.65-1.87)
	>28	12 (2.3)	-	0.84 (0.46-1.52)	0.95 (0.52-1.76)
Hours of vigorous physical exercise in	0	171 (2.9)		1.00	1.00
week prior to questionnaire	1-3	163 (2.9)	15176	0.98 (0.79-1.22)	0.95 (0.75-1.18)
completion ²	≥4	109 (2.9)	-	0.99 (0.78-1.27)	1.03 (0.80-1.32)
Hours of light physical exercise in	0-4	189 (3.6)		1.00	1.00
week prior to questionnaire	5-9	140 (2.8)	15192	0.76 (0.61-0.95)	0.87 (0.69-1.10)
completion ³	≥10	117 (2.4)	-	0.64 (0.51-0.81)	0.89 (0.70-1.14)
Hours of lower-impact physical activity	0	274 (3.1)		1.00	1.00
in week prior to questionnaire	1	88 (3.1)	15176	0.97 (0.76-1.24)	0.90 (0.70-1.16)
completion ⁴	≥2	83 (2.3)	-	0.73 (0.57-0.94)	0.76 (0.59-0.98)
	≤6	41 (3.1)		1.22 (0.86-1.73)	1.15 (0.80-1.64)
Estimated average hours of sleep per	7	113 (3.1)	45000	1.20 (0.94-1.53)	1.24 (0.97-1.59)
night in month prior to questionnaire	8	159 (2.6)	15223	1.00	1.00
completion⁵	≥9	133 (3.3)	-	1.28 (1.02-1.62)	1.26 (0.99-1.60)

Minimally adjusted odd ratios (95% CI) with a P-value <0.10 are emboldened.

1, adjusted for age, sex, duration of participation and test frequency

2, defined as exercise of sufficient intensity to make the participant breathless or to raise their heart rate significantly, such as heavy physical work, strenuous gardening (e.g. vigorous digging, landscaping) swimming, jogging, aerobics, football, tennis, cycling, gym workout, reported to the nearest hour

3, defined as exercise that did not make the participant breathless, such as light gardening, walking, including walking for pleasure or exercise, walking to the shops, walking to work, reported to the nearest hour

4, defined as exercise to improve flexibility or core strength such as yoga, tai chi or pilates, reported to the nearest hour

5, reported to the nearest hour

Table 3. Underlying conditions, medication use, vaccination status and risk of test-confirmedCOVID-19: crude and minimally-adjusted odds ratios

		Number (%) with incident test-confirmed COVID-19	Total number	Crude odds ratio (95% CI)	Minimally adjusted odds ratio (95% Cl) ¹
Underlying conditions		50VID-13			,
	Excellent	89 (2.9)	_	1.00	1.00
	Very good	174 (2.9)	_	1.00 (0.77-1.29)	1.06 (0.81-1.38)
Self-rated general health	Good	120 (3.0)	15225	1.02 (0.77-1.35)	1.03 (0.77-1.37)
	Fair	52 (3.2)	_	1.10 (0.78-1.56)	0.99 (0.70-1.42)
	Poor No	11 (2.4)		0.84 (0.45-1.59)	0.75 (0.40-1.43)
Self-rated anxiety or depression	Yes	316 (2.8) 130 (3.2)	- 15216	<u>1.00</u> 1.13 (0.92-1.39)	<u>1.00</u> 0.91 (0.73-1.12)
	<25	177 (2.4)		1.00	1.00
Body mass index, kg/m ²	25-30	168 (3.5)	15189	1.48 (1.19-1.83)	1.58 (1.27-1.97)
,	>30	100 (3.4)		1.45 (1.13-1.86)	1.37 (1.06-1.77)
Asthma	No	384 (3.0)	15227	1.00	1.00
Asuma	Yes	62 (2.5)	- 15227	0.82 (0.62-1.07)	0.67 (0.51-0.88)
Atopic disease ²	No	349 (3.1)	- 15227	1.00	1.00
	Yes	97 (2.5)	IULLI	0.80 (0.64-1.01)	0.65 (0.51-0.82)
COPD	No	438 (2.9)	- 15227	1.00	1.00
	Yes No disbotos	8 (2.5)		0.84 (0.41-1.70)	1.14 (0.55-2.34)
	No diabetes Pre-diabetes	<u>415 (3.0)</u> 14 (3.1)	-	1.00 1.06 (0.62-1.82)	1.00 1.38 (0.79-2.41)
Diabetic status	Type 1 diabetes	3 (2.8)	- 15206	0.96 (0.30-3.02)	0.81 (0.25-2.62)
	Type 2 diabetes	13 (2.1)	-	0.70 (0.40-1.22)	0.92 (0.52-1.62)
	No	432 (3.0)		1.00	1.00
Heart disease ³	Yes	14 (2.4)	- 15227	0.80 (0.47-1.38)	1.28 (0.73-2.25)
Artarial diagona 4	No	431 (3.0)	15007	1.00	1.00
Arterial disease ⁴	Yes	15 (1.9)	- 15227	0.63 (0.38-1.07)	0.91 (0.53-1.57)
Hypertension	No	378 (3.2)	15227	1.00	1.00
	Yes	68 (2.1)	10221	0.64 (0.50-0.84)	0.88 (0.67-1.17)
Kidney disease	No	441 (3.0)	- 15227	1.00	1.00
,	Yes	5 (1.6)	-	0.54 (0.22-1.31)	0.62 (0.25-1.52)
Major neurological conditions⁵	<u>No</u> Yes	440 (3.0)	- 15227	1.00	<u>1.00</u> 0.62 (0.27-1.41)
	Never	<u>6 (1.5)</u> 410 (3.0)		0.50 (0.22-1.12) 1.00	1.00
Cancer	Past (cured or in remission)	33 (2.6)	15227	0.87 (0.61-1.25)	1.12 (0.77-1.63)
	Present (active treatment in progress)	3 (2.2)		0.72 (0.23-2.27)	0.89 (0.28-2.87)
	No	446 (2.9)	- 15140	1.00	1.00
Immunodeticiency ⁰		0 (0.0)		NA	NA
Immunodeficiency ⁶	Yes	<u> </u>			
Immunodeficiency ⁶ Periodontitis ⁷	No	<mark>240 (2.7)</mark>	<mark>15227</mark>	1.00	<u>1.00</u>
-	No Yes	240 (2.7) 129 (3.3)	<u>15227</u>	1.20 (0.96-1.49)	<mark>1.30 (1.04-1.62)</mark>
Periodontitis ⁷	No	<mark>240 (2.7)</mark>	<u>15227</u>		
Periodontitis ⁷ Medications	No Yes	240 (2.7) 129 (3.3)		1.20 (0.96-1.49)	<mark>1.30 (1.04-1.62)</mark>
Periodontitis ⁷	No Yes Missing	240 (2.7) 129 (3.3) 77 (3.05)	_ <u>15227</u> - - - 15227	<u>1.20 (0.96-1.49)</u> 1.12 (0.86-1.45)	1.30 (1.04-1.62) 1.13 (0.86-1.49)
Periodontitis ⁷ Medications Statins	No Yes Missing No Yes No	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0)	- 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 (0.42-0.77) 1.00	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00
Periodontitis ⁷ Medications	No Yes Missing No Yes No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1)		1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99)	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32)
Periodontitis ⁷ Medications Statins ACE inhibitors	No Yes Missing No Yes No Yes No	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0)	- 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 1.00	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00
Periodontitis ⁷ Medications Statins	No Yes Missing No Yes No Yes No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4)	- 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 0.80	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20)
Periodontitis ⁷ Medications Statins ACE inhibitors	No Yes Missing No Yes No Yes No Yes No	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0)	- 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 0.80 0.80 (0.60-1.08)	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors	No Yes Missing No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5)	- 15227 - 15227 - 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 0.80 0.80 (0.60-1.08) 1.00 0.83	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00 0.68 (0.48-0.97)
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors	No Yes Missing No Yes No	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0)	- 15227 - 15227 - 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 0.80 0.80 (0.60-1.08) 1.00 0.83	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 0.93 (0.67-1.29) 1.00 0.90 0.90 (0.62-1.32) 1.00 0.88 0.65-1.20) 1.00 1.00 0.68 0.68 (0.48-0.97) 1.00 0.68
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids	No Yes Missing No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3)	- 15227 - 15227 - 15227 - 15227 - 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 0.80 0.80 (0.60-1.08) 1.00 0.83	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00 0.68 (0.48-0.97)
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants	No Yes Missing No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2)	- 15227 - 15227 - 15227 - 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.12 (0.86-1.45) 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 0.80 0.80 (0.60-1.08) 1.00 0.83 0.43 (0.22-0.84) 1.00 1.50	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 0.93 (0.67-1.29) 1.00 0.90 0.90 (0.62-1.32) 1.00 0.88 0.68 (0.65-1.20) 1.00 0.68 0.68 (0.48-0.97) 1.00 1.00 0.39 (0.20-0.77) 1.00 1.19
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants Selective serotonin re-uptake inhibitors (SSRIs)	No Yes Missing No Yes No	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2) 424 (2.9)	- 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.12 (0.86-1.45) 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 0.80 0.80 (0.60-1.08) 1.00 0.83 0.43 (0.22-0.84) 1.00 1.50 1.00 1.50	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 0.93 (0.67-1.29) 1.00 0.90 0.90 (0.62-1.32) 1.00 0.88 0.68 (0.65-1.20) 1.00 0.68 0.39 (0.20-0.77) 1.00 1.19
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants Selective serotonin re-uptake	No Yes Missing No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2) 424 (2.9) 22 (3.4)	- 15227 - 15227 - 15227 - 15227 - 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.12 (0.86-1.45) 0.57 (0.42-0.77) 1.00 0.68 0.68 (0.47-0.99) 1.00 0.80 0.80 (0.60-1.08) 1.00 0.83 0.43 (0.22-0.84) 1.00 1.50 1.00 1.50 1.00 1.19	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00 0.68 (0.48-0.97) 1.00 0.39 (0.20-0.77) 1.00 1.19 (0.86-1.64) 1.00 1.17 (0.75-1.83)
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants Selective serotonin re-uptake inhibitors (SSRIs) Non-SSRI antidepressants	No Yes Missing No Yes No	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2) 424 (2.9) 22 (3.4) 427 (3.0)	- 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227	$\begin{array}{r} \hline 1.20 & (0.96-1.49) \\ \hline 1.12 & (0.86-1.45) \\ \hline 1.12 & (0.86-1.45) \\ \hline 0.57 & (0.42-0.77) \\ \hline 1.00 \\ \hline 0.68 & (0.47-0.99) \\ \hline 1.00 \\ \hline 0.80 & (0.60-1.08) \\ \hline 1.00 \\ \hline 0.83 & (0.59-1.18) \\ \hline 1.00 \\ \hline 0.43 & (0.22-0.84) \\ \hline 1.00 \\ \hline 1.50 & (1.09-2.05) \\ \hline 1.00 \\ \hline 1.19 & (0.77-1.84) \\ \hline 1.00 \\ \hline \end{array}$	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00 0.68 (0.48-0.97) 1.00 0.39 (0.20-0.77) 1.00 1.19 (0.86-1.64) 1.00 1.17 (0.75-1.83)
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants Selective serotonin re-uptake inhibitors (SSRIs)	No Yes Missing No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2) 424 (2.9) 22 (3.4) 427 (3.0) 19 (2.2)	- 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227	$\begin{array}{r} \hline 1.20 & (0.96-1.49) \\ \hline 1.12 & (0.86-1.45) \\ \hline 1.12 & (0.86-1.45) \\ \hline 0.57 & (0.42-0.77) \\ \hline 1.00 \\ \hline 0.68 & (0.47-0.99) \\ \hline 1.00 \\ \hline 0.80 & (0.60-1.08) \\ \hline 1.00 \\ \hline 0.83 & (0.59-1.18) \\ \hline 1.00 \\ \hline 0.43 & (0.22-0.84) \\ \hline 1.00 \\ \hline 1.50 & (1.09-2.05) \\ \hline 1.00 \\ \hline 1.19 & (0.77-1.84) \\ \hline 1.00 \\ \hline 0.74 & (0.46-1.17) \\ \hline \end{array}$	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00 0.68 (0.48-0.97) 1.00 0.39 (0.20-0.77) 1.00 1.19 (0.86-1.64) 1.00 1.17 (0.75-1.83) 1.00 1.01 (0.62-1.63)
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants Selective serotonin re-uptake inhibitors (SSRIs) Non-SSRI antidepressants	No Yes Missing No Yes No	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2) 424 (2.9) 22 (3.4) 427 (3.0) 19 (2.2) 444 (2.9)	- 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227	1.20 (0.96-1.49) 1.12 (0.86-1.45) 1.00 0.57 0.57 (0.42-0.77) 1.00 0.68 0.80 (0.60-1.08) 1.00 0.83 0.83 (0.59-1.18) 1.00 0.43 1.50 (1.09-2.05) 1.00 1.19 0.74 (0.46-1.17) 1.00 0.74	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00 0.68 (0.48-0.97) 1.00 0.39 (0.20-0.77) 1.00 1.19 (0.86-1.64) 1.00 1.10 (0.75-1.83) 1.00 1.01 (0.62-1.63) 1.00
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants Selective serotonin re-uptake inhibitors (SSRIs) Non-SSRI antidepressants Angiotensin receptor blockers	No Yes Missing No Yes No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2) 424 (2.9) 22 (3.4) 427 (3.0) 19 (2.2) 444 (2.9) 2 (1.8)	- 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227	$\begin{array}{r} \hline 1.20 & (0.96-1.49) \\ \hline 1.12 & (0.86-1.45) \\ \hline 1.12 & (0.86-1.45) \\ \hline 0.57 & (0.42-0.77) \\ \hline 1.00 \\ \hline 0.68 & (0.47-0.99) \\ \hline 1.00 \\ \hline 0.80 & (0.60-1.08) \\ \hline 1.00 \\ \hline 0.83 & (0.59-1.18) \\ \hline 1.00 \\ \hline 0.43 & (0.22-0.84) \\ \hline 1.00 \\ \hline 1.50 & (1.09-2.05) \\ \hline 1.00 \\ \hline 1.19 & (0.77-1.84) \\ \hline 1.00 \\ \hline 0.74 & (0.46-1.17) \\ \hline 1.00 \\ \hline 0.61 & (0.15-2.46) \\ \hline \end{array}$	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00 0.68 (0.48-0.97) 1.00 0.39 (0.20-0.77) 1.00 1.19 (0.86-1.64) 1.00 1.10 (0.75-1.83) 1.00 1.01 (0.62-1.63) 1.00 0.73 (0.18-3.06)
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants Selective serotonin re-uptake inhibitors (SSRIs) Non-SSRI antidepressants Angiotensin receptor blockers	No Yes Missing No Yes No	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2) 422 (3.4) 427 (3.0) 19 (2.2) 444 (2.9) 2 (1.8) 424 (3.0)	- 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227 - 15227	$\begin{array}{r} \hline 1.20 & (0.96-1.49) \\ \hline 1.12 & (0.86-1.45) \\ \hline \\ \hline \\ 1.12 & (0.86-1.45) \\ \hline \\ 0.57 & (0.42-0.77) \\ \hline \\ 1.00 \\ \hline \\ 0.68 & (0.47-0.99) \\ \hline \\ 1.00 \\ \hline \\ 0.80 & (0.60-1.08) \\ \hline \\ 1.00 \\ \hline \\ 0.83 & (0.59-1.18) \\ \hline \\ 1.00 \\ \hline \\ 0.43 & (0.22-0.84) \\ \hline \\ 1.00 \\ \hline \\ 1.00 \\ \hline \\ 1.19 & (0.77-1.84) \\ \hline \\ 1.00 \\ \hline \\ 0.74 & (0.46-1.17) \\ \hline \\ 1.00 \\ \hline \\ 0.61 & (0.15-2.46) \\ \hline \\ 1.00 \\ \hline \end{array}$	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 0.93 (0.67-1.29) 1.00 0.90 0.90 (0.62-1.32) 1.00 0.88 0.88 (0.65-1.20) 1.00 0.68 0.39 (0.20-0.77) 1.00 1.19 1.19 (0.86-1.64) 1.00 1.17 1.00 1.01 1.00 0.73 1.00 1.01
Periodontitis ⁷ Medications Statins ACE inhibitors Proton pump inhibitors Inhaled corticosteroids Systemic Immunosuppressants Selective serotonin re-uptake inhibitors (SSRIs) Non-SSRI antidepressants Angiotensin receptor blockers Vitamin K antagonists	No Yes Missing No Yes No Yes	240 (2.7) 129 (3.3) 77 (3.05) 398 (3.2) 48 (1.8) 415 (3.0) 31 (2.1) 395 (3.0) 51 (2.4) 410 (3.0) 36 (2.5) 437 (3.0) 9 (1.3) 401 (2.8) 45 (4.2) 424 (2.9) 22 (3.4) 427 (3.0) 19 (2.2) 444 (2.9) 2 (1.8)	- 15227 - 15227	$\begin{array}{r} \hline 1.20 & (0.96-1.49) \\ \hline 1.12 & (0.86-1.45) \\ \hline 1.12 & (0.86-1.45) \\ \hline 0.57 & (0.42-0.77) \\ \hline 1.00 \\ \hline 0.68 & (0.47-0.99) \\ \hline 1.00 \\ \hline 0.80 & (0.60-1.08) \\ \hline 1.00 \\ \hline 0.83 & (0.59-1.18) \\ \hline 1.00 \\ \hline 0.43 & (0.22-0.84) \\ \hline 1.00 \\ \hline 1.50 & (1.09-2.05) \\ \hline 1.00 \\ \hline 1.19 & (0.77-1.84) \\ \hline 1.00 \\ \hline 0.74 & (0.46-1.17) \\ \hline 1.00 \\ \hline 0.61 & (0.15-2.46) \\ \hline \end{array}$	1.30 (1.04-1.62) 1.13 (0.86-1.49) 1.00 0.93 (0.67-1.29) 1.00 0.90 (0.62-1.32) 1.00 0.88 (0.65-1.20) 1.00 0.68 (0.48-0.97) 1.00 0.39 (0.20-0.77) 1.00 1.19 (0.86-1.64) 1.00 1.10 (0.75-1.83) 1.00 1.01 (0.62-1.63) 1.00 0.73 (0.18-3.06)

		Number (%) with incident test-confirmed COVID-19	Total number	Crude odds ratio (95% Cl)	Minimally adjusted odds ratio (95% Cl) ¹
H2-receptor antagonists	No	442 (2.9)	- 15227	1.00	1.00
	Yes	4 (4.6)	19221	1.60 (0.59-4.39)	1.36 (0.48-3.83)
Calcium channel blockers	No	417 (3.0)	- 15227	1.00	1.00
	Yes	29 (2.0)	13227	0.64 (0.44-0.93)	0.91 (0.61-1.36)
Inhaled bronchodilators ⁸	No	14 (2.0)	- 15227	1.00	1.00
	Yes	411 (3.0)	- 15227	0.84 (0.59-1.20)	0.54 (0.31-0.94)
Non storaidal anti inflammatan druga	No	421 (3.0)	15007	1.00	1.00
Non-steroidal anti-inflammatory drugs	Yes	25 (2.0)	- 15227	0.66 (0.44-0.99)	0.84 (0.55-1.28)
Sodium-glucose co-transporter-2	No	444 (2.9)	- 15227	1.00	1.00
(SGLT2) inhibitors	Yes	2 (2.5)		0.86 (0.21-3.51)	0.95 (0.23-4.00)
	No	422 (3.0)	- 15227	1.00	1.00
Anti-platelet drugs	Yes	24 (2.5)		0.83 (0.55-1.26)	1.29 (0.83-1.99)
Cay barmana tharany	No	401 (2.8)	- 15227	1.00	1.00
Sex hormone therapy	Yes	45 (4.0)		1.44 (1.05-1.97)	1.19 (0.85-1.65)
Dana astana al	No	430 (2.9)	45007	1.00	1.00
Paracetamol	Yes	16 (2.5)	- 15227	0.84 (0.51-1.39)	0.89 (0.53-1.50)
NA - 4E - marking	No	434 (2.9)	45007	1.00	1.00
Metformin	Yes	12 (2.8)	- 15227	0.94 (0.52-1.67)	1.28 (0.71-2.31)
Disal south such as	No	441 (2.9)	45007	1.00	1.00
Bisphosphonates	Yes	5 (1.9)	- 15227	0.65 (0.27-1.58)	0.76 (0.31-1.90)
Vaccinations					
	No	40 (2.0)		1.00	1.00
BCG-vaccinated	Yes	366 (3.1)	15197	1.55 (1.12-2.16)	1.36 (0.97-1.90)
	Unsure	38 (2.5)	-	1.23 (0.79-1.93)	1.26 (0.80-2.00)
	No	131 (2.6)		1.00	1.00
MMR-vaccinated	Yes	226 (3.5)	- 11451	1.38 (1.11-1.71)	1.04 (0.81-1.32)

BCG, M. bovis Bacille Calmette Guérin; MMR, measles mumps and rubella

Minimally adjusted odd ratios (95% CI) with a P-value <0.10 are bold.

1, adjusted for age, sex, duration of participation and test frequency

2, defined by atopic eczema/dermatitis and/or hayfever/allergic rhinitis

3, defined as coronary artery disease or heart failure

4, defined as ischaemic heart disease, peripheral vascular disease or cerebrovascular disease

5, defined as stroke, transient ischaemic attack, dementia, Parkinson's disease, multiple sclerosis or motor neurone disease

6, defined as HIV, primary immune deficiency or other immunodeficiency

7, defined as being present if participant answered 'yes' to any of the three questions relating to gum disease / dental health listed in Table S1

8, defined as β -2-adrenoceptor agonists or anticholinergics

		Number (%) with incident test-confirmed COVID-19	Total number	Crude odds ratio (95% CI)	Minimally adjusted odds ratio (95% Cl) ¹
Diet					
	None	419 (2.9)	_	1.00	1.00
Dietary restrictions	Vegetarian ²	22 (3.2)	15227	1.11 (0.72-1.72)	0.89 (0.57-1.40)
	Vegan ³	5 (2.2)		0.75 (0.31-1.83)	0.60 (0.24-1.49)
Number of portions of fruit,	Q1	78 (3.5)	_	1.00	1.00
vegetables, and salad intake per	Q2	158 (3.1)	- 15188	0.88 (0.67-1.17)	0.90 (0.68-1.20)
day in week prior to questionnaire	Q3	87 (3.0)	-	0.85 (0.62-1.16)	0.89 (0.64-1.22)
completion, quartiles	Q4	120 (2.4)		0.66 (0.49-0.88)	0.73 (0.54-0.99)
Number of portions of dairy	0-1	114 (2.8)	-	1.00	1.00
products per day in week prior to	2	142 (3.2)	- 15183	1.15 (0.90-1.48)	1.18 (0.91-1.53)
questionnaire completion	3-5	99 (2.7)	-	0.96 (0.73-1.27)	1.06 (0.80-1.41)
queedennane completion	≥6	91 (2.9)		1.03 (0.78-1.37)	1.24 (0.93-1.65)
Total number of portions of fish	Q1	94 (3.8)	-	1.00	1.00
(oily or white) intake in the week	Q2	79 (3.2)	- 15213	0.85 (0.63-1.15)	0.99 (0.73-1.36)
prior to questionnaire completion	Q3	111 (2.7)	-	0.71 (0.53-0.93)	0.88 (0.66-1.18)
	Q4	162 (2.6)		0.70 (0.54-0.90)	0.95 (0.72-1.25)
Portions of oily fish intake in the	0	210 (3.7)	_	1.00	1.00
week prior to guestionnaire	1	133 (2.7)	- 15220	0.72 (0.58-0.90)	0.86 (0.69-1.08)
completion	2	71 (2.4)	-	0.64 (0.49-0.85)	0.80 (0.60-1.06)
	≥3	32 (2.1)		0.57 (0.39-0.83)	0.76 (0.52-1.13)
Portions of white fish intake in the	0	131 (3.3)	- 15216	1.00	1.00
week prior to guestionnaire	1	170 (2.8)		0.83 (0.66-1.04)	0.99 (0.78-1.26)
completion	2	92 (2.6)		0.76 (0.58-1.00)	0.95 (0.72-1.26)
	≥3	53 (3.3)		0.98 (0.71-1.35)	1.16 (0.83-1.61)
Number of cups of non-alcoholic	Q1	104 (3.0)	_	1.00	1.00
fluids per day in the week prior to	Q2	75 (2.9)	- 15177	0.98 (0.73-1.32)	1.03 (0.76-1.41)
questionnaire completion, quartiles	Q3	116 (2.5)	-	0.84 (0.64-1.10)	0.81 (0.62-1.07)
	Q4	149 (3.4)		1.14 (0.88-1.47)	0.99 (0.76-1.29)
Micronutrient supplement use		004 (07)		4.00	1.00
Multivitamin supplement	No	331 (2.7)	- 15227	1.00	1.00
	Yes	115 (3.6)		1.33 (1.07-1.65)	1.12 (0.89-1.40)
Vitamin A supplement	No	445 (2.9)	- 15227	1.00	1.00
	Yes	1 (1.1)	-	0.38 (0.05-2.73)	0.43 (0.06-3.15)
Vitamin C supplement	No	397 (2.9)	- 15227	1.00	1.00
	Yes	49 (3.1)		1.09 (0.80-1.47)	1.03 (0.76-1.41)
Vitamin D supplement	No	305 (3.2)	- 15227	1.00	1.00
	Yes	141 (2.5)		0.80 (0.65-0.98)	0.80 (0.65-0.99)
Zinc supplement	No	425 (2.9)	- 15227	1.00	1.00
	Yes	21 (2.8)		0.97 (0.62-1.51)	0.93 (0.58-1.46)
Iron supplement	No	423 (2.9)	- 15227	1.00	1.00
	Yes	23 (4.6)		1.63 (1.06-2.51)	1.27 (0.82-1.98)
Probiotic supplement	No Yes	426 (3.0) 20 (2.2)	- 15227	1.00 0.72 (0.46-1.13)	1.00
				1.00	0.69 (0.44-1.10)
Fish oil, krill oil or other omega-3	No	400 (3.0)	- 15227	0.91 (0.67-1.25)	
supplements	Yes No	46 (2.7)		1.00	0.98 (0.71-1.35)
Cod liver oil supplement	Yes	<u>409 (2.9)</u> 37 (3.0)	- 15227	1.03 (0.73-1.45)	1.29 (0.91-1.84)
Garlie or garlie powder (alligin)	No	439 (2.9)		1.00	1.00
Garlic or garlic powder (allicin) supplement	Yes	7 (2.3)	- 15227	0.77 (0.36-1.63)	0.93 (0.43-2.02)
••	No			1.00	1.00
Selenium supplement		445 (3.0)	- 15227		
	Yes	1 (0.6)		0.21 (0.03-1.47)	0.20 (0.03-1.46)

Table 4. Diet, supplemental micronutrient intake and risk of test-confirmed COVID-19: crude and minimally-adjusted odds ratios

Minimally adjusted odd ratios (95% CI) with a P-value <0.10 are emboldened.

1, adjusted for age, sex, duration of participation and test frequency

2, defined as excluding meat and fish, but not eggs or cow's milk, from the diet

3, defined as excluding meat, fish, eggs and cow's milk from the diet

Table 5. Independent risk factors for test-confirmed COVID-19: final multivariable model (n=14,556)

Here 10-39.99 1.20 (0.88-212) Age, years 40-49.99 1.20 (0.88-212) Soc. 50-59.99.0 1.12 (0.85-1.83) Soc. Female 1.00 270.00 0.74 (0.39-1.41) - Sex Female 1.00 Male 0.97 (0.76-1.23) - Mixed/Mutiple/other ethnic groups 1.53 (0.32-2.53) - White 1.00 - - Mixed/Mutiple/other ethnic groups 1.53 (0.32-2.53) - - White 0.01 - - - - Highest educational level attained 0.97 (0.76-1.23) - - - - Mixed/Mutiple/other ethnic groups 1.53 (0.32-2.53) 0.08 - <th>Characteristic</th> <th>Categories</th> <th>Fully-adjusted odds ratio (95% Cl)¹</th> <th>P for trend</th> <th>E value (upper or lower bound of 95% Cl)¹⁰</th>	Characteristic	Categories	Fully-adjusted odds ratio (95% Cl) ¹	P for trend	E value (upper or lower bound of 95% Cl) ¹⁰
Age, years 40-49.99 1.20 (0.69-2.10) 0.08 50-59.99 1.12 (0.65-1.93) 0.08 Sex Female 1.00 Sex Male 0.07 (1.03) - Ethnicity Female 1.00 - Male 0.07 (1.07-1.23) - Ethnicity Male Infinitin 2.26 (1.33-3.91) - Mixed/Multiple/obser ethnic groups 1.53 (0.52-2.53) - - White 1.00 - - - - Highest educational level attained Primary/Secondary 1.00 - - - Index of multiple deprivation (IMD) rank, G2 0.90 (0.87-1.20) 0.44 - - Quarties Q3 0.87 (0.65-1.16) - - - - Housing Privately renting rom council 0.96 (0.65-1.46) - - - Housing Privately renting rom council 0.96 (0.65-1.46) - - - Housing Privately renting rom council 0.96 (0			1.00	_	•••••••
Age, years 50.59.99 1.12 (0.65-193) 0.08 50.69.91 0.80 (0.44.1.44) 270.00 0.74 (0.39-1.41) Sex Female 0.07 280 (0.41.44) 399 Sex Female 0.07 (0.76-1.23) 3.99 Ethnicity Mixed/Multiple/other ethnic groups 1.53 (0.92-2.53) HigherFurther (A levels) 0.90 (6.1-1.33) 0.08 Higher (Higher (Higher (-				_	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Age vears			- 0.08	
270.00 0.74 (0.39-1.41) Sex Female 0.00 Male 0.97 (0.76-1.23) - Stain/Asian British 2.28 (1.33-3.91) - Black/African/Caribbear/Black British 1.84 (0.70.4.82) - Winte 1.00 - Highest educational level attained Primary/Secondary 1.00 Primary/Secondary 1.00 - Highest educational level attained College 0.82 (0.58-1.16) 0.08 College 0.82 (0.58-1.16) 0.04 - Mate of multiple deprivation (IMD) rank, C2 0.89 (0.67-1.20) 0.44 Q3 0.87 (0.65-1.16) - - OW more own home 1.00 - - Housing Privately renting 0.96 (0.53-1.40) - Number of people per bedroom ² 50.50 1.00 - - Schoolchildren (aged 5-15 years) at nome with participant Yes 1.16 (0.86-1.56) - - Schoolchildren (aged 5-15 years) at nome with participant Yes 1.10 (0.93	Ngo, youro				
Sex Female 1.00				_	
Sex Male 0.97 (0.76-123) Asian/Asian British 228 (133.391) 3.99 Ethnicity Black/Arican/Caribbean/Black British 1.84 (0.704.82) Higher/Antiple/other ethnic groups 1.53 (0.92-2.53) Higher/Eurher (A levels) 0.90 (0.61-1.33) 0.08 Higher/Eurher (A levels) 0.90 (0.61-1.33) 0.08 Ordege 0.82 (0.38-1.16) 0.44 guartiles Q4 (teast deprived) 1.11 (0.84-1.48) 0.44 Quartiles Q.90 (0.65-1.16) 0.44 Housing Privately renting 0.96 (0.63-1.46) Housing Privately renting 0.96 (0.63-1.46) Number of people per bedroom? 50.50 1.00 Number of people per bedroom? 50.50 Schoolchildren (aged 5-15 years) at No No 1.00 Number of people per bedroom? Yes 1.16 (0.86-1.62) </td <td></td> <td></td> <td></td> <td></td> <td></td>					
Asian/Asian British 2.28 (1.33-3.91) 3.99 Ethnicity Black/Atrican/Cartish 1.64 (0.704.82)	Sex				
Ethnicity Black/African/Caribbean/Black British 1.84 (0.70-4.82)					2 00 /1 00
Initiality Mixed/Multiple/other ethnic groups 1.53 (0.922-5.3) White 1.00			· · · · ·	_	<u>3.99 (1.99</u>
White 1.00 Higher/Excondary 1.00 Higher/Excondary 0.90 (0.61-1.3) Oclege 0.22 (0.58-1.16) Post-graduate 0.74 (0.51-1.07) Of (most deprived) 1.11 (0.84-1.48) Q2 0.90 (0.67-1.20) Q3 0.87 (0.65-1.16) Q4 (east deprived) 1.00 Mortgage 1.19 (0.91-1.56) Privately renting 0.96 (0.63-1.46) Number of people per bedroom ² 50.50 >50.50 1.00 >0.50-0.99 1.24 (0.93-1.66) 1.00-199 1.67 (125-2.23) Schoolchildren (aged 5-15 years) at No 1.00 No 1.00 Yes 1.16 (0.88-1.56) Number of visits to shops and other Aprix oppoint on the households in No 1.00 No 1.04 (0.64-1.68) Any visits to from other households in No 1.00 No 1.01 (0.64-1.20) Output: places in week prior to questionnaire completion Yes 1.31 (1.06-1.20) Number of potions of frui	Ethnicity		· · · · ·		
Primary/Secondary 1.00 Highest educational level attained Primary/Secondary 0.08 0.08 Higher/Further (A levels) 0.90 (0.61:1.33) College 0.08 0.08 Index of multiple deprivation (IMD) rank, quartiles (Imost deprived) 1.11 (0.84:1.48) Q2 0.47 (0.51:1.07) 0.44 Value of the private of people per bedroom? Q4 (teast deprived) 1.00 0.44 Housing Privately renting 0.96 (0.63:1.74) Others 0.44 (0.81:1.66) Privately renting - Number of people per bedroom? 50.50 1.00 - - >0.50.99 1.24 (0.93:1.66) 1.00-1.99 - - - >0.50.99 1.24 (0.93:1.67) 1.00-1.99 - - - >0.01 (15:3) Yes 1.16 (0.86:1.56) - - Schoolchildren (aged 5-15 years) at nome with participant Yes 1.04 (0.64:1.68) - - No 1.00 - - - - - Stelding No 1.00 - - - -				_	
Higher/Further (A levels) 0.90 (0.61-1.3). 0.62 0.82 (0.58-1.15). 0.74 (0.51-1.07) 0.08 Index of multiple deprivation (IMD) rank, quartiles Q2 0.90 (0.67-1.20). Q3 0.44 0.44 Q3 0.87 (0.65-1.16). Q4 (least deprived) 1.00 0.44 Housing Privately renting 0.96 (0.63-1.74). Owns own home 0.44 Housing Privately renting 0.96 (0.63-1.74). Others - Housing Privately renting 0.96 (0.63-1.74). Others - Number of people per bedroom ² 50.50 1.00 - >0.50-0.99 1.24 (0.93-1.66). 1.00-1.99 - - >0.50 at home No 1.00 - - >0.50 at home No 1.00 - - >0.50 at home No 1.00 - - >0.50 at home No <					
College 0.82 (0.58-1.16) 0.06 Post-graduate 0.74 (0.51-1.07) 0.1 (most deprived) 1.11 (0.84-1.48) 0.44 Q2 0.90 (0.67-1.60) 0.44 0.44 0.44 Q3 0.87 (0.65-1.16) 0.44 0.44 0.44 Housing Provaley renting 0.96 (0.63-1.46) Housing Privately renting 0.96 (0.63-1.46) Number of people per bedroom ² 50.50 1.00 1.00-1.99 1.67 (1.25-2.23) 2.00 2.04 (1.55-3.60) 3.52 Schoolchildren (aged 5-15 years) at No No 1.00 Schoolchildren (aged 5-15 years) at No No				_	
Post-graduate 0.74 (0.511.07) Q1 (most deprived) 1.11 (0.84-1.48) Q2 0.90 (0.67-1.20) Q3 0.87 (0.65-1.16) Q4 (least deprived) 1.00 Owns own home 1.00 Housing Privately renting 0.96 (0.63-1.74) Privately renting 0.96 (0.53-1.74) Yes 0.96 (0.53-1.74) Yes 0.99 (0.63-1.46) Privately renting 0.96 (0.53-1.74) Yes 1.34 (0.61-2.21) Number of people per bedroom ² 50.50 1.00 2.00 2.04 (1.15-3.60) Schoolchildren (aged 5-15 years) at No 1.00 Yes 1.16 (0.86-1.56)	Highest educational level attained			- 0.08	
Index of multiple deprivation (IMD) rank, parties Or (most deprived) 1.11 (0.84.1.48) (0.87 (0.65-1.16)) 0.44 Q2 0.90 (0.67-1.20) Q3 0.87 (0.65-1.16) 0.44 Housing Mortgage 1.10 (0.91.1.56) Privately renting 0.96 (0.63.1.46) Privately renting Housing Privately renting 0.96 (0.63.1.74) Others Number of people per bedroom ² 50.50 1.00 -0.50-0.99 1.24 (0.93.1.66) 1.00-1.99 -0.50-0.99 1.24 (0.93.1.47) Privately renting Schoolchildren (aged 5-15 years) at nome with participant No 1.00 Schoolchildren fouseholds in week prior to questionnaire completion No 1.00 Shielding No 1.00 1.96 (1.29-2.98) Q3				_	
Index of multiple deprivation (IMD) rank, quartiles Q2 0.90 (0.67-1.20) Q3 0.44 Quartiles Q4 (least deprived) 1.00 0.45 0.45 Housing Owns own home 1.00 0.05 0.65 0.65 Housing Privately renting 0.96 (0.63-1.74) 0.44 0.41 0.41 Housing Privately renting 0.96 (0.63-1.74) 0.74 0.00 0.74 Number of people per bedroom ² 50.50 1.00 - - - 20.50 1.00 20.60 2.04 (1.15-3.60) - - - Schoolchildren (aged 5-15 years) at nome with participant Yes 1.17 (0.93-1.47) - - - - Shielding No 1.00 -					
Qa 0.87 (0.65.1.16) 0.44 Q4 (least deprived) 1.00	ndex of multiple deprivation (IMD) rank				
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$				- 0.44	
Owns own home 1.00 Housing Mortgage 1.19 (0.91-1.66) Privately renting 0.96 (0.63-1.46) Number of people per bedroom ² 50.50 1.00 Schoolchildren (aged 5-15 years) at non- No 1.00 Number of people per bedroom ² 2.00 2.04 (1.15-3.60) Schoolchildren (aged 5-15 years) at non- No 1.00 Nome 1.00 1.00 Schoolchildren (aged 5-15 years) at non- No 1.00 Schoolchildren (aged 5-15 years) No 1.00 1.95 Schoolchildren (aged 5-15 years)<				_	
Housing Mortgage 1.19 (0.91-1.56)					
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Housing			_	
Renting from council 0.96 (0.53-1.74) Others 1.34 (0.81-2.21) Number of people per bedroom ² $20.50 - 99$ 1.24 (0.93-1.66) $20.50-0.99$ 1.24 (0.93-1.66) $20.50 - 92$ Schoolchildren (aged 5-15 years) at one with participant No $1.00 - 1.99$ $1.66 (0.86-1.56)$ Schoolchildren (aged 5-15 years) at one with participant No 1.00 3.52 Schoolchildren (aged 5-15 years) at one with participant No 1.00 3.62 Ogg at home No 1.00 $7es$ $1.16 (0.86-1.56)$ $7es$ Shielding No 1.00 $7es$ $1.31 (1.06-1.62)$ $7es$ Number of visits to from other households in week prior to questionnaire completion ³ Qd $2.21 (1.43.343)$ 20.001 3.33 Questionnaire completion ³ Qd $2.21 (1.43.343)$ 20.001 3.33 Questionnaire completion ³ Qd $2.21 (1.43.343)$ 20.001 3.33 Questionnaire completion No 1.00 $2.22 (1.04.21.95)$ $$ 2.04 Q					
Others 1.34 (0.81-2.21) Yumber of people per bedroom ² ≤ 0.50 1.00 > $20.50-0.99$ 1.22 (0.93-1.66) 2.73 > 20.00 2.04 (1.15-3.60) 3.52 Schoolchildren (aged 5-15 years) at nome with participant No 1.00 Sog at home No 1.00 Shielding No 1.00 Yes 1.14 (0.86-1.56) Shielding No 1.00 Yes 1.04 (0.64-1.68) Any visits to/from other households in questionnaire completion No 1.00 Yes 1.01 (0.6-1.62) 1.95 Q2 1.96 (1.29-2.98) <0.011				_	
Number of people per bedroom ² $\frac{50.50}{2.00}$ 1.00 >0.50-0.99 1.24 (0.93-1.66) 20.00 >2.00 2.04 (1.15-3.60) 3.52 Schoolchildren (aged 5-15 years) at nome with participant No 1.00 Dog at home No 1.00 Schoolchildren (aged 5-15 years) at nome with participant No 1.00 Schoolchildren (aged 5-15 years) at nome with participant No 1.00 Schoolchildren (aged 5-15 years) at nome with participant No 1.00 Schoolchildren (aged 5-15 years) at nome No 1.00 Schoolchildren (aged 5-15 years) at nome No 1.00 Schoolchildren (aged 5-15 years) at nome No 1.00		· · · · · · · · · · · · · · · · · · ·		_	
$ 20.50-0.99 \\ 1.00-1.99 \\ 1.67 (1.25-2.23) \\ 22.00 \\ 2.04 (1.15-3.60) \\ 3.52 \\ 22.00 \\ 2.04 (1.15-3.60) \\ 3.52 \\ 22.00 \\ 2.04 (1.15-3.60) \\ 3.52 $	Number of people per bedroom ²	≤0.50			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		>0.50-0.99	1.24 (0.93-1.66)		
≥ 2.00 2.04 (1.15- 3.60) 3.52 Schoolchildren (aged 5-15 years) at nome with participant No 1.00 Dog at home No 1.00 Dog at home No 1.00 Shielding No 1.00 Shielding No 1.00 Any visits to/from other households in week prior to questionnaire completion No 1.00 Vumber of visits to shops and other questionnaire completion ³ Q1 1.00 Q2 1.96 ($1.29-2.98$) 20.001 $\frac{3.33}{3.84}$ Q4 2.63 ($1.69-4.10$) Travel to work/study in week prior to questionnaire completion No 1.00 2.04 Travel to worker Health or social care worker 1.35 ($1.00-1.82$) 2.04 Sumber of portions of fruit, vegetables, and salad intake per day in week prior o questionnaire completion, quartiles Q1 1.00 0.21 0.31 Q4 0.86 ($0.63-1.19$) 0.22 0.83 (0				- <0.001	<mark>2.73 (1.81</mark>
home with participant Yes 1.16 (0.86-1.56)				_	3.52 (1.43
Dog at home No 1.00 Shielding No 1.00 Shielding No 1.00 Any visits to/from other households in week prior to questionnaire completion No 1.00 Yes 1.04 (0.64-1.68) - Number of visits to shops and other questionnaire completion ³ No 1.00 Q2 1.96 (1.29-2.98) 3.84 Q3 2.21 (1.43.3.43) - Q4 2.63 (1.69-4.10) - Travel to work/study in week prior to questionnaire completion No 1.00 Yes 1.36 (0.93-1.99) - No 1.00 - Yes 1.36 (0.03-1.69) - Not currently working or studying 1.27 (0.82-1.95) - Not currently working or studying 1.21 (21.98) - Q2 1.00 (0.75-1.35) - 2.34 Q4 0.86 (0.63-1.19) - 2.34 No 1.00 - 2.34 2.34 Q4 0.83 (0.63-1.09) - 2.34	Schoolchildren (aged 5-15 years) at	No	1.00		
Yes $1.17 (0.93-1.47)$ Shielding No 1.00 Yes $1.04 (0.64-1.68)$ Any visits to/from other households in week prior to questionnaire completion No 1.00 Number of visits to shops and other indoor public places in week prior to questionnaire completion ³ Q1 1.00 3.33 Q2 $1.96 (1.29-2.98)$ $Q.001$ 3.33 $Q.4$ $2.63 (1.69-4.10)$ 4.70 Travel to work/study in week prior to questionnaire completion No 1.00 $$ 2.001 3.33 3.44 $2.63 (1.69-4.10)$ $$ $$ Frontline worker No 1.00 $$	home with participant	Yes	1.16 (0.86-1.56)		
ShieldingNo1.00Yes1.04 (0.64-1.68)Any visits to/from other households in week prior to questionnaire completionNo1.00Yes1.31 (1.06-1.62)Number of visits to shops and other ndoor public places in week prior to questionnaire completion ³ Q11.00Q21.96 (1.29-2.98) Q3 2.21 (1.43-3.43) Q4 2.63 (1.69-4.10)Travel to work/study in week prior to questionnaire completionNo1.00Yes1.36 (0.93-1.99) YesNot currently working or studying1.27 (0.82-1.95)Not currently working or studying1.27 (0.82-1.95)Not currently working or studying1.00Health or social care worker1.35 (1.00-1.82) Q2Other frontline worker1.00Health or social care worker1.39 (0.75-1.35) Q3Qa0.86 (0.63-1.19)No1.00Q20.83 (0.63-1.09)Yes0.93 (0.75-1.16)Ours of lower-impact physical activity completion ⁴ 0No1.00Setimated average hours of sleep per night in month prior to questionnaire completion ⁵ 0.316Alcohol consumption in week prior toNoneNone1.00Alcohol consumption in week prior toNoneAlcohol consumption in week prior toNoneNone1.00Alcohol consumption in week prior toNoneNone1.00Alcohol consumption in week prior toNoneNone1.00 <td>Dog at home</td> <td></td> <td>1.00</td> <td>_</td> <td></td>	Dog at home		1.00	_	
Yes 1.04 (0.64-1.68) Any visits to/from other households in week prior to questionnaire completion No 1.00 1.95 Number of visits to shops and other questionnaire completion ³ Q1 1.00 1.95 Q2 1.96 (1.29-2.98) <0.001					
Any visits to/from other households in week prior to questionnaire completionNo1.00Yes1.31 (1.06-1.62)-1.95Number of visits to shops and other ndoor public places in week prior to questionnaire completion3Q11.00Q21.96 (1.29-2.98) Q3Q.2.21 (1.43-3.43) Q4<0.001	Shielding				
week prior to questionnaire completionYes1.31 (1.06-1.62)Number of visits to shops and other indoor public places in week prior to questionnaire completion3 $\begin{array}{c} Q1 & 1.00 \\ \hline Q2 & 1.96 (1.29-2.98) \\ \hline Q3 & 2.21 (1.43-3.43) \\ \hline Q4 & 2.63 (1.69-4.10) \\ \hline Pres & 1.36 (0.93-1.99) \\ \hline Not currently working or studying & 1.27 (0.82-1.95) \\ \hline Not currently working or studying & 1.20 (0.75-1.16) \\ \hline Not currently working or studying & 1.20 (0.75-1.16) \\ \hline Not currently working or studying & 1.2$					
Number of visits to shops and other indoor public places in week prior to questionnaire completion3 $\begin{array}{c} Q1 \\ Q2 \\ Q3 \\ Q4 \\ Q4 \\ Q4 \\ Q4 \\ Q4 \\ Q4 \\ Q4$	Any visits to/from other households in				_
Number of visits to snops and other indoor public places in week prior to questionnaire completion ³ Travel to work/study in week prior to questionnaire completion Frontline worker No Travel to work/study in week prior to questionnaire completion Frontline worker No No Currently working or studying No No No No No No No No No No	week prior to questionnaire completion				<mark>1.95 (1.31</mark>
ndoor public places in week prior to questionnaire completion ³ $\frac{Q2}{Q3}$ 1.96 ($1.29-2.98$) $Q4$ <0.001 $\frac{3.38}{3.84}$ $Q4$ 2.63 ($1.69-4.10$) 4.70 Travel to work/study in week prior to questionnaire completion No 1.00 $$ Frontline worker No 1.00 $$ 2.04 Frontline worker Health or social care worker 1.35 ($1.00-1.82$) $$ 2.04 Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles $Q1$ 1.00 -2.34 Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles $Q1$ 0.31 0.31 Q3 1.04 ($0.75-1.35$) $Q3$ 0.31 0.31 Taking vitamin D supplement No 1.00 0.33 ($0.75-1.16$) 0.22 Hours of lower-impact physical activity n week prior to questionnaire completion 4 0.83 ($0.63-1.09$) 0.22 0.31^6 0.31^6 Estimated average hours of sleep per right in month prior to questionnaire completion ⁵ 56 1.14 ($0.79-1.65$) 7 1.14 ($0.79-1.66$) 1.90 <tr< td=""><td>Number of visits to shops and other</td><td></td><td></td><td>_</td><td>_</td></tr<>	Number of visits to shops and other			_	_
questionnaire completion3 $\frac{Q3}{Q4}$ $2.21(1.43-3.43)$ 3.64 $\overline{Q4}$ $2.63(1.69-4.10)$ 4.70 $\overline{Q4}$ $2.63(1.69-4.10)$ 4.70 $\overline{Q4}$ $2.63(1.69-4.10)$ 4.70 $\overline{Q4}$ $2.63(1.69-4.10)$ 4.70 $\overline{Q4}$ 1.00 $7es$ $1.36(0.93-1.99)$ $$ $\overline{Q1}$ 1.00 1.00 $$ 2.04 $\overline{Q1}$ 1.00 1.00 $2.21(1.42-3.43)$ 2.234 $\overline{Q1}$ 1.00 $0.75-1.35$ 0.31 $\overline{Q2}$ $1.00(0.75-1.35)$ 0.31 0.31 $\overline{Q2}$ $1.00(0.75-1.16)$ 0.31 0.31 $\overline{Q4}$ $0.86(0.63-1.19)$ 0.31 $\overline{Q4}$ $0.86(0.63-1.19)$ 0.22 $\overline{Q4}$ $0.86(0.63-1.19)$ 0.22 $\overline{Q4}$ $0.83(0.63-1.09)$ 0.22 $\overline{Q4}$ $0.83(0.63-1.09)$ 0.22 $\overline{Q4}$ $0.83(0.63-1.09)$ 0.31^6 $\overline{Q4}$ $0.81(0.08-1.48)$ 0.31^6 $\overline{Q2}$ $1.00(0.79-1.65)$ 7 $\overline{Q4}$ $0.81(0.08-1.48)$ 0.31^6 $\overline{Q4}$ $0.81(0.08-1.48)$ 0.31^6 $\overline{Q4}$ $0.81(0.08-1.48)$ 0.31^6 $\overline{Q4}$ $0.81(0.08-1.48)$ 0.39 $\overline{Q4}$				- <0 001	<mark>3.33 (1.90</mark>
Q4 $2.63(1.69-4.10)$ 4.70 Travel to work/study in week prior to questionnaire completionNo 1.00 $$ Yes $1.36(0.93-1.99)$ Not currently working or studying $1.27(0.82-1.95)$ $$ Frontline worker 1.00 1.00 $$ $$ Health or social care worker $1.35(1.00-1.82)$ Other frontline worker $$ 2.04 Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles 01 Q2 $1.00(0.75-1.35)$ Q3 0.31 Taking vitamin D supplementNo 1.00 Yes 0.31 0.31 Taking vitamin D supplement 0 Yes $0.93(0.75-1.16)$ 1.00 0.22 Estimated average hours of sleep per night in month prior to questionnaire completion ⁵ $\frac{<6}{7}$ $1.14(0.88-1.48)$ 8 1.00 0.31^6 Alcohol consumption in week prior to Noe 1.7 $1.14(0.85-1.44)$ 0.39 0.39				_	<mark>3.84 (2.21</mark>
Yes $1.36 (0.93-1.99)$ Not currently working or studying $1.27 (0.82-1.95)$ Frontline workerNo 1.00 Health or social care worker $1.35 (1.00-1.82)$ $0.82-1.95)$ Frontline worker $1.49 (1.12-1.98)$ $$ 2.04 2.34 Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles $Q1$ $Q2$ $Q4$ $1.00 (0.75-1.35)$ $Q3$ $1.04 (0.74-1.45)$ $Q4$ $0.86 (0.63-1.19)$ Taking vitamin D supplementNo 1.00 Yes 0.31 Hours of lower-impact physical activity completion 4 $0.86 (0.63-1.19)$ 1.00 0.22 Estimated average hours of sleep per night in month prior to questionnaire completion 5 0.31^6 0.31^6 See the structure of the st	dex of multiple deprivation (IMD) rank artiles busing mber of people per bedroom ² hoolchildren (aged 5-15 years) at me with participant og at home ielding y visits to/from other households in tek prior to questionnaire completion mber of visits to shops and other loor public places in week prior to estionnaire completion ³ avel to work/study in week prior to				<mark>4.70 (2.77</mark>
questionnaire completion $\frac{Yes}{Not}$ $1.36(0.93-1.99)$ $$ Not currently working or studying $1.27(0.82-1.95)$ $$ Frontline worker 1.00 1.00 Health or social care worker $1.35(1.00-1.82)$ $$ Other frontline worker $1.49(1.12-1.98)$ 2.34 Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles $Q1$ 1.00 $Q2$ $1.04(0.74-1.45)$ 0.31 $Q4$ $0.86(0.63-1.19)$ 0.31 Taking vitamin D supplement No 1.00 Hours of lower-impact physical activity n week prior to questionnaire completion 4 $0.83(0.63-1.09)$ Estimated average hours of sleep per night in month prior to questionnaire completion 5 56 $1.14(0.79-1.65)$ 7 $1.14(0.88-1.48)$ 0.31^6 8 1.00 1.00 29 $1.29(1.01-1.66)$ 1.90 Alcohol consumption in week prior to 1.7 $1.11(0.85-1.44)$	Travel to work/study in week prior to			_	
Not currently working or studying $1.27 (0.82-1.95)$ Frontline workerNo 1.00 Health or social care worker $1.35 (1.00-1.82)$ Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles $Q1$ 1.00 Q2 $1.00 (0.75-1.35)$ Q3 0.31 Q4 $0.86 (0.63-1.19)$ 0.31 Taking vitamin D supplementNo 1.00 Hours of lower-impact physical activity completion 4 0 $0.33 (0.75-1.16)$ Hours of lower-impact physical activity completion 4 0 $0.83 (0.63-1.09)$ Estimated average hours of sleep per night in month prior to questionnaire completion5 56 $1.14 (0.78-1.31)$ 8 0.22 Alcohol consumption in week prior to $None$ 1.00 $1.29 (1.01-1.66)$ 1.90 None 1.00 0.31^6 1.7 $1.11 (0.85.1.44)$ 0.30					
Frontline workerHealth or social care worker $1.35 (1.00-1.82)$ $1.49 (1.12-1.98)$ 2.04 Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartilesQ1 1.00 0.31 Q2 $1.00 (0.75-1.35)$ Q4 $0.86 (0.63-1.19)$ 0.31 Taking vitamin D supplementNo 1.00 Yes $0.93 (0.75-1.16)$ 0.22 Hours of lower-impact physical activity n week prior to questionnaire completion 4 0 0.22 0.31 Estimated average hours of sleep per night in month prior to questionnaire completion 5 0 $1.14 (0.78-1.31)$ 29 0.21^6 Alcohol consumption in week prior toNone 1.00 $1.29 (1.01-1.66)$ 1.90 None 1.00 0.31^6 0.31^6 0.31^6 0.31^6 0.31^6					
Other frontline worker $1.49 (1.12-1.98)$ 2.34 Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles $\begin{array}{c} Q1 & 1.00 \\ \hline Q2 & 1.00 (0.75-1.35) \\ \hline Q3 & 1.04 (0.74-1.45) \\ \hline Q4 & 0.86 (0.63-1.19) \\ \hline \\ $				_	0.04/4.07
Number of portions of fruit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles $\begin{array}{c} Q1 & 1.00 \\ Q2 & 1.00 & (0.75-1.35) \\ Q3 & 1.04 & (0.74-1.45) \\ \hline Q4 & 0.86 & (0.63-1.19) \\ \hline Q4 & 0.86 & (0.63-1.19) \\ \hline \\ \hline \\ Taking vitamin D supplement \\ Hours of lower-impact physical activityn week prior to questionnaire completion 4 \\ \hline \\ completion 4 & 2 \\ \hline \\ completion 5 & 2 \\ \hline \\ \hline \\ Res & 1.00 \\ \hline \\ \hline \\ \hline \\ \hline \\ Res & 1.00 \\ \hline \\$	-rontline worker				2.04 (1.02
Number of portions of truit, vegetables, and salad intake per day in week prior to questionnaire completion, quartiles $Q2$ $1.00 (0.75-1.35)$ $Q3$ 0.31 Taking vitamin D supplementNo $1.04 (0.74-1.45)$ $Q4$ $0.86 (0.63-1.19)$ 0.31 Taking vitamin D supplementNo 1.00 Yes $0.93 (0.75-1.16)$ 0.22 Hours of lower-impact physical activity n week prior to questionnaire completion 4 0 1.00 1.00 0.22 Estimated average hours of sleep per night in month prior to questionnaire completion5 ≤ 6 7 $1.14 (0.79-1.65)$ 7 0.31^6 Alcohol consumption in week prior toNone 1.00 1.7 0.30					<mark>2.34 (1.4</mark> 9
and salad intake per day in week prior to questionnaire completion, quartiles $\frac{U2}{Q3}$ $1.00 (0.75-1.35)$ $Q4$ 0.31 Taking vitamin D supplementNo 1.00 Yes $0.93 (0.75-1.16)$ 0.22 Hours of lower-impact physical activity completion 40 1.00 Yes $0.93 (0.75-1.16)$ Hours of lower-impact physical activity completion 40 $0.93 (0.75-1.16)$ 0.22 $0.83 (0.63-1.09)$ 0.22 Estimated average hours of sleep per night in month prior to questionnaire completion 5 $1.14 (0.79-1.65)$ 7 0.31^6 $1.29 (1.01-1.66)$ $1.29 (1.01-1.66)$ 1.90 Alcohol consumption in week prior to $None$ 1.00 None 1.00 0.39	Number of portions of fruit. vegetables.			_	
Q_3 $1.04 (0.74-1.45)$ Q_4 $0.86 (0.63-1.19)$ Taking vitamin D supplement No No 1.00 Hours of lower-impact physical activity 0 0 1.00 1 $1.01 (0.78-1.31)$ 0 $0.83 (0.63-1.09)$ 22 $0.83 (0.63-1.09)$ 22 $0.83 (0.63-1.09)$ 22 $0.83 (0.63-1.09)$ 23 $0.81 (0.79-1.65)$ 7 $1.14 (0.88-1.48)$ 8 1.00 29 $1.29 (1.01-1.66)$ 1.7 $1.11 (0.85.1.44)$ 0.30				- 0.31	
Q4 $0.86 (0.63-1.19)$ No 1.00 Yes $0.93 (0.75-1.16)$ Hours of lower-impact physical activity 0 1.00 n week prior to questionnaire 0 1.00 $0.93 (0.75-1.16)$ completion 4 22 $0.83 (0.63-1.09)$ 0.22 Estimated average hours of sleep per night in month prior to questionnaire completion ⁵ $\frac{<6}{7}$ $1.14 (0.88-1.48)$ 0.31^6 8 1.00 0.31^6 $\frac{1.90}{1.29}$ Alcohol consumption in week prior to None 1.00 0.39	1 2 1			_	
Yes $0.93 (0.75-1.16)$ Hours of lower-impact physical activity n week prior to questionnaire completion 4 0 1.00 1 $1.01 (0.78-1.31)$ ≥ 2 0.22 Estimated average hours of sleep per night in month prior to questionnaire completion5 ≤ 6 $1.14 (0.79-1.65)$ 7 0.31^6 $\frac{6}{29}$ $1.29 (1.01-1.66)$ 1.90 Alcohol consumption in week prior to $None$ 1.00 $1-7$ $1.11 (0.85.1.44)$ 0.39	· · ·				
Yes $0.93 (0.75-1.16)$ Hours of lower-impact physical activity 0 1.00 n week prior to questionnaire 1 $1.01 (0.78-1.31)$ 0.22 completion 4 ≥ 2 $0.83 (0.63-1.09)$ 0.22 Estimated average hours of sleep per hight in month prior to questionnaire completion 5 ≤ 6 $1.14 (0.79-1.65)$ 0.31^6 $\frac{2}{7}$ $1.29 (1.01-1.66)$ 1.29 0.31^6 1.90 Alcohol consumption in week prior to $\frac{None}{1.7}$ $1.11 (0.85.1.44)$ 0.39	Taking vitamin D supplement			_	
n week prior to questionnaire completion 4 1 1.01 (0.78-1.31) 0.22 2 0.83 (0.63-1.09) 0.22 Estimated average hours of sleep per night in month prior to questionnaire completion ⁵ ≤ 6 1.14 (0.79-1.65) 7 1.14 (0.88-1.48) 0.316 8 1.00 ≥ 9 1.29 (1.01-1.66) Alcohol consumption in week prior to None 1.7 1.11 (0.85-1.44)					
Scompletion 4 ≥ 2 0.83 (0.63-1.09) Estimated average hours of sleep per night in month prior to questionnaire completion ⁵ ≤ 6 1.14 (0.79-1.65) 7 1.14 (0.88-1.48) 0.316 8 1.00 1.29 (1.01-1.66) 9 1.29 (1.01-1.66) 1.90 Alcohol consumption in week prior to $\frac{None}{1.7}$ 1.11 (0.85-1.44) 0.39					
$ \begin{array}{c} \leq 6 & 1.14 \ (0.79-1.65) \\ \hline 7 & 1.14 \ (0.88-1.48) \\ \hline 8 & 1.00 \\ \hline \\ \geq 9 & 1.29 \ (1.01-1.66) \\ \hline \\ \hline \\ Alcohol \ consumption \ in \ week \ prior \ to \\ \hline \\ 1.7 & 111 \ (0.85.1.44) \\ \hline \\ \hline \\ 0.30 \\ \hline \\ \hline \\ \hline \\ \hline \\ 1.90 \\ \hline \\ $				0.22	
Estimated average hours of sleep per hight in month prior to questionnaire completion ⁵ $ \begin{array}{c} 7 \\ 8 \\ \hline 9 \\ \hline 1.29 \\ 1.29 \\ 1.29 \\ 1.29 \\ 1.29 \\ 1.20 \\ \hline 1.20 \\$					
$\frac{1.14 (0.00^{-1.46})}{1.00} = 0.31^{6}$ $\frac{1.14 (0.00^{-1.46})}{1.00} = 0.31^{6}$ $\frac{1.00}{1.29 (1.01 - 1.66)} = \frac{1.00}{1.00}$ Alcohol consumption in week prior to $\frac{1.7}{1.7} = 1.11 (0.85 + 1.44) = 0.30$	Estimated average hours of sleep per			_	
Sompletion ≥ 9 1.29 (1.01-1.66) 1.90 Alcohol consumption in week prior to None 1.00				- 0.31 ⁶	
Alcohol consumption in week prior to $\frac{\text{None}}{1.7}$ 1.11 (0.85.1.44) 0.30	completion ⁵			_	1 00 /1 1/
Alcohol consumption in week prior to $\frac{1}{1}$					<mark>1.90 (1.1</mark> 1
	Alcohol consumption in week prior to			0.30	
questionnaire completion, units 8-14 1.08 (0.79-1.47)	questionnaire completion, units			0.39	

Characteristic	Categories	Fully-adjusted odds ratio (95% Cl) ¹	P for trend	E value (upper or lower bound of 95% Cl) ¹⁰
	15-21	1.45 (1.01-2.08)	_	
	22-28	1.23 (0.72-2.11)		
	>28	0.83 (0.43-1.60)		
	<25	1.00	_	
Body mass index, kg/m ²	25-30	1.50 (1.19-1.89)	0.004	2.37 (1.67)
	>30	1.39 (1.06-1.84)		<mark>2.13 (1.31)</mark>
Asthma	No	1.00	_	
	Yes	0.82 (0.55-1.24)		
Atopic disease ⁷	No	1.00	_	
Atopic disease	Yes	0.75 (0.59-0.97)		2.00 (1.21)
	No	<mark>1.00</mark>	_	
Periodontitis ⁸	Yes	<mark>1.20 (0.95-1.52)</mark>	_ <mark></mark>	
	Missing	<mark>1.03 (0.77-1.37)</mark>		
Svetemie immuneauppressente	No	1.00	_	
Systemic immunosuppressants	Yes	0.47 (0.22-0.99)		3.68 (1.11)
Inhaled corticosteroids	No	1.00		
Innaled controsteroids	Yes	1.01 (0.55-1.84)		
Inhaled bronchodilators9	No	1.00		
	Yes	1.07 (0.61-1.88)		
	No	1.00	_	
BCG-vaccinated	Yes	1.38 (0.97-1.96)		
	Unsure	1.24 (0.78-1.99)		
Duration of participation, days		1.00 (1.00-1.00)		
Swab test frequency		1.62 (1.52-1.72)		

Abbreviation: BCG, M. bovis Bacillus Calmette Guérin

1, adjusted for age, sex, duration of participation, test frequency, ethnicity, highest educational level attained, IMD rank, hours of sleep per night, housing, number of people per bedroom, presence of schoolchildren at home, dog at home, shielding, visits to/from other households, visits to shops and other indoor places, travel to work or study, frontline worker status, fruit, vegetable and salad intake, supplemental vitamin D intake, low-impact physical activity, alcohol intake, body mass index, history of asthma, history of atopic disease, use of systemic immunosuppressants, use of inhaled corticosteroids, use of inhaled bronchodilators and BCG vaccination status.

2, adjusted odds ratio per additional 0.5 people per bedroom 1.26 (95% CI 1.11 to 1.43)

3, adjusted odds ratio per extra visit per week 1.05 (95% CI 1.01 to 1.09)

4, defined as exercise to improve flexibility or core strength such as yoga, tai chi or pilates, reported to the nearest hour

5, reported to nearest hour


6, only applies to sleeping categories below 8 hours

7, defined by atopic eczema/dermatitis and/or hayfever/allergic rhinitis

8, defined as being present if participant answered 'yes' to any of the three questions relating to gum disease / dental health listed in Table S1

9, defined as β -2-adrenoceptor agonists or anticholinergics

10, E-values are presented for associations which are significant with P<0.05. For protective associations, the upper bound of the 95% confidence interval for the E-value is presented. For non-protective associations, the lower bound of the 95% confidence interval for the E-value is presented. **Figure 1.** Dose-response relationship between body mass index (A) and age (B) and risk of incident test-defined COVID-19 using restricted cubic spline analysis. The multivariable models were mutually adjusted for all factors presented in Table 5.



References

1. Aburto JM, Kashyap R, Schöley J, et al. Estimating the burden of COVID-19 pandemic on mortality, life expectancy and lifespan inequality in England and Wales: A population-level analysis. *MedRxiv* 2020.

2. Miller IF, Becker AD, Grenfell BT, Metcalf CJE. Disease and healthcare burden of COVID-19 in the United States. *Nat Med* 2020; **26**(8): 1212-7.

3. Pifarre IAH, Acosta E, Lopez-Casasnovas G, et al. Years of life lost to COVID-19 in 81 countries. *Scientific reports* 2021; **11**(1): 3504.

4. Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ* 2020; **371**: m3731.

5. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; **584**(7821): 430-6.

6. Venkatesan P. The changing demographics of COVID-19. *The lancet Respiratory medicine* 2020; **8**(12): e95.

7. Ward H, Atchison C, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. *MedRxiv* 2020.

 Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet* 2020; **396**(10247): 313-9.
 Bhala N, Curry G, Martineau AR, Agyemang C, Bhopal R. Sharpening the global focus on

ethnicity and race in the time of COVID-19. Lancet 2020; **395**(10238): 1673-6.

10. Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer? *The lancet Diabetes & endocrinology* 2020; **8**(9): 735-6.

11. Hamer M, Kivimaki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. *Brain, behavior, and immunity* 2020; **87**: 184-7.

12. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med* 2020; **26**(7): 1037-40.

13. Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nature communications* 2020; **11**(1): 5749.

14. Cramér H. Mathematical Methods of Statistics. Princeton: Princeton University Press; 1946.

Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology* 1990; 1(1):
 43-6.

16. Ding P, VanderWeele TJ. Sensitivity Analysis Without Assumptions. *Epidemiology* 2016; **27**(3): 368-77.

17. Linden A, Mathur MB, VanderWeele TJ. Conducting sensitivity analysis for unmeasured confounding in observational studies using E-values: The evalue package. *The Stata Journal* 2020; **20**(1): 162-75.

18. Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol* 2020; **146**(1): 203-6 e3.

19. The OpenSAFELY Collaborative, Mathur R, Rentsch CT, et al. Ethnic differences in COVID-19 infection, hospitalisation, and mortality: an OpenSAFELY analysis of 17 million adults in England. *MedRxiv* 2020.

Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. *Obes Rev* 2020; **21**(11): e13128.
 Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. 2020; **10:e040402**.

22. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. *Lancet Infect Dis* 2020; **20**(9): 1034-42.

23. Ma H, Zhou T, Heianza Y, Qi L. Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank. *Am J Clin Nutr* 2021; **113**(5): 1275-81.

24. Louca P, Murray B, Klaser K, et al. Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study app. *BMJ Nutrition, Prevention & Coversion Prevention & Prevention & Prevention & Coversion & Coversio & Coversion & Coversio & Coversion & Coversion & Coversio*

25. Doll R, Hill AB. Mortality in Relation to Smoking: Ten Years' Observations of British Doctors. *Br Med J* 1964; **1**(5396): 1460-7 CONCL.